PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 8621643-2 1996 The 190-kDa multidrug resistance protein (MRP) has recently been associated with the transport of cysteinyl leukotrienes and several glutathione (GSH) S-conjugates. cysteinyl-leukotriene 98-120 ATP binding cassette subfamily C member 1 Homo sapiens 12-40 8621643-2 1996 The 190-kDa multidrug resistance protein (MRP) has recently been associated with the transport of cysteinyl leukotrienes and several glutathione (GSH) S-conjugates. cysteinyl-leukotriene 98-120 ATP binding cassette subfamily C member 1 Homo sapiens 42-45 8621643-19 1996 The identification of an MRP-specific mAb that inhibits LTC4 transport and prevents photolabeling of MRP by LTC4, provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes. cysteinyl-leukotriene 178-200 ATP binding cassette subfamily C member 1 Homo sapiens 25-28 8621643-19 1996 The identification of an MRP-specific mAb that inhibits LTC4 transport and prevents photolabeling of MRP by LTC4, provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes. cysteinyl-leukotriene 178-200 ATP binding cassette subfamily C member 1 Homo sapiens 101-104 8621643-19 1996 The identification of an MRP-specific mAb that inhibits LTC4 transport and prevents photolabeling of MRP by LTC4, provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes. cysteinyl-leukotriene 178-200 ATP binding cassette subfamily C member 1 Homo sapiens 101-104 8621644-2 1996 In addition to its ability to confer resistance to a range of natural product type chemotherapeutic agents, multidrug resistance protein (MRP) has been shown to transport the cysteinyl leukotriene, LTC4, and several other glutathione (GSH) S-conjugates. cysteinyl-leukotriene 175-196 ATP binding cassette subfamily C member 1 Homo sapiens 108-136 8621644-2 1996 In addition to its ability to confer resistance to a range of natural product type chemotherapeutic agents, multidrug resistance protein (MRP) has been shown to transport the cysteinyl leukotriene, LTC4, and several other glutathione (GSH) S-conjugates. cysteinyl-leukotriene 175-196 ATP binding cassette subfamily C member 1 Homo sapiens 138-141 8091318-3 1994 If the cysteinyl leukotrienes cause aspirin-induced asthmatic reactions, inhibition of the 5-lipoxygenase pathway should prevent aspirin-induced bronchospasm. cysteinyl-leukotriene 7-29 arachidonate 5-lipoxygenase Homo sapiens 91-105 7589406-3 1995 Strategies for inhibition of cysteinyl leukotriene effects include antagonism of cysteinyl leukotriene receptors and inhibition of 5-lipoxygenase activity. cysteinyl-leukotriene 29-50 arachidonate 5-lipoxygenase Homo sapiens 131-145 7827126-2 1995 We have partially purified and characterized LTC4 synthase, the enzyme responsible for cysteinyl LT formation, from rat renal microsomes and have investigated this enzyme activity in nephritic rats. cysteinyl-leukotriene 87-99 leukotriene C4 synthase Rattus norvegicus 45-58 8021512-5 1994 Therefore, the inhibitory effects of PKC activation on cysteinyl leukotriene formation in intact cells was attributable to effects on the LTC4 synthase enzyme. cysteinyl-leukotriene 55-76 leukotriene C4 synthase Homo sapiens 138-151 7559381-7 1995 Thus, developmentally segregated regulation of the prostanoid and cysteinyl leukotriene pathways in lineage-related committed mast cell progenitors reveals the pleiotropism of this effector cell of allergic inflammation, a cytokine/growth factor basis for preferential expression of pathways of eicosanoid biosynthesis, and the particular role of IL-3 in regulating the expression of the proteins of the 5-LO/LTC4 synthase pathway. cysteinyl-leukotriene 66-87 interleukin 3 Mus musculus 347-351 7559381-7 1995 Thus, developmentally segregated regulation of the prostanoid and cysteinyl leukotriene pathways in lineage-related committed mast cell progenitors reveals the pleiotropism of this effector cell of allergic inflammation, a cytokine/growth factor basis for preferential expression of pathways of eicosanoid biosynthesis, and the particular role of IL-3 in regulating the expression of the proteins of the 5-LO/LTC4 synthase pathway. cysteinyl-leukotriene 66-87 leukotriene C4 synthase Mus musculus 409-422 8025768-1 1994 Inhaled PAF provokes bronchoconstriction, causes peripheral blood neutropenia with rebound neutrophilia, and generates urinary production of the bronchoconstrictor eicosanoids, thromboxane (TX)A2, and the cysteinyl leukotrienes. cysteinyl-leukotriene 205-227 PCNA clamp associated factor Homo sapiens 8-11 8088308-15 1994 Our results suggest that injection of CVF and the liberation of high amounts of the anaphylatoxins, C3a and C5a, induces the release of TXA2, which contributes to the early renal effects and the formation of cysteinyl-leukotrienes which play an important role in the late phase of systemic complement activation. cysteinyl-leukotriene 208-230 complement C5 Rattus norvegicus 108-111 8122190-2 1993 We have recently demonstrated that contact activation of the intrinsic coagulation cascade in vitro is accompanied not only by thromboxane (TX) B2 generation but also by the formation of 5-lipoxygenase-derived cysteinyl-leukotrienes (LT). cysteinyl-leukotriene 210-232 arachidonate 5-lipoxygenase Homo sapiens 187-201 8497495-8 1993 Our results suggest the in vivo effects of C5a to be mediated by cysteinyl leukotrienes, which may be important in the pathogenesis of septic, anaphylactic or traumatic shock. cysteinyl-leukotriene 65-87 complement C5 Rattus norvegicus 43-46 8342619-8 1993 These results point to an rC5a-mediated synthesis and release of cysteinyl leukotrienes and TxA2, whereas PAF does not seem to be released after intravenous rC5a in rats. cysteinyl-leukotriene 65-87 complement C5 Rattus norvegicus 26-30 1654958-1 1991 Tumor necrosis factor-alpha is believed to be an important mediator of endotoxaemia and septic shock, the effects of which are thought to be mediated through the generation of cysteinyl-leukotrienes, thromboxane A2 and other prostanoids. cysteinyl-leukotriene 176-198 tumor necrosis factor Homo sapiens 0-27 8385438-9 1993 There was a significant positive correlation between TNF-alpha and both LTB4 and the total cysteinyl leukotriene sputum content. cysteinyl-leukotriene 91-112 tumor necrosis factor Homo sapiens 53-62 1414692-2 1992 Both PGE2 (1-100 nM) and SIN-1 (30-300 microM) inhibited release of LTB4 and cysteinyl-LT from RPN in a concentration-dependent manner. cysteinyl-leukotriene 77-89 MAPK associated protein 1 Homo sapiens 25-30 1632288-4 1992 In addition, inhibition of cysteinyl-leukotriene (cys-LT) release could contribute to the protective effect of SIN-1 observed. cysteinyl-leukotriene 27-48 MAPK associated protein 1 Homo sapiens 111-116 1632288-4 1992 In addition, inhibition of cysteinyl-leukotriene (cys-LT) release could contribute to the protective effect of SIN-1 observed. cysteinyl-leukotriene 50-56 MAPK associated protein 1 Homo sapiens 111-116 1661723-2 1991 This study was performed to evaluate whether PAF-induced bronchoconstriction in vivo could be mediated through the release of the bronchoconstrictor eicosanoids, thromboxane (Tx) A2 and the cysteinyl leukotrienes. cysteinyl-leukotriene 190-212 PCNA clamp associated factor Homo sapiens 45-48 1661723-9 1991 Inhaled PAF leads to the secondary generation of cysteinyl leukotrienes and TxA2, and it is possible that these mediate some of the acute effects of inhaled PAF in vivo. cysteinyl-leukotriene 49-71 PCNA clamp associated factor Homo sapiens 8-11 1661723-9 1991 Inhaled PAF leads to the secondary generation of cysteinyl leukotrienes and TxA2, and it is possible that these mediate some of the acute effects of inhaled PAF in vivo. cysteinyl-leukotriene 49-71 PCNA clamp associated factor Homo sapiens 157-160 2224126-6 1990 After GM-CSF administration a distinct increase in urinary cysteinyl leukotrienes was found in the cytopenic and the RAEB patients that ranged from 2.3- to 57-fold and 2.4- to 333-fold, respectively. cysteinyl-leukotriene 59-81 colony stimulating factor 2 Homo sapiens 6-12 34790737-1 2021 Background: Our previous studies demonstrated that cysteinyl leukotrienes receptor 1 (CysLT1R) knockout, pharmacological blockade, or hippocampus knockdown produced beneficial effects against Alzheimer"s disease (AD); however, whether CysLT1R upregulation has deleterious effects on AD remains elusive. cysteinyl-leukotriene 51-73 cysteinyl leukotriene receptor 1 Mus musculus 86-93 2161395-0 1990 Hypoxia and CCl4-induced liver injury, but not acidosis, impair metabolism of cysteinyl leukotrienes in perfused rat liver. cysteinyl-leukotriene 78-100 C-C motif chemokine ligand 4 Rattus norvegicus 12-16 14616869-9 2003 FcepsilonRI cross-linking resulted in intracellular calcium mobilization, histamine release and synthesis of cysteinyl leukotrienes. cysteinyl-leukotriene 109-131 Fc epsilon receptor Ia Homo sapiens 0-11 35245090-7 2022 Cysteinyl leukotrienes cause gallbladder contraction through their cognate receptor CysLTR1, prompting emptying and closing. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 84-91 34692913-4 2021 We recently demonstrated that nasal solitary chemosensory (brush) cells can generate robust levels of cysteinyl leukotrienes in response to stimulation with calcium ionophore, aeroallergens, and danger-associated molecules, such as ATP and UTP, and this mechanism depends on brush cell expression of the purinergic receptor P2Y2. cysteinyl-leukotriene 102-124 purinergic receptor P2Y, G-protein coupled 2 Mus musculus 324-328 34542380-1 2021 The human Guanine Protein coupled membrane Receptor 17 (hGPR17), an orphan receptor that activates uracil nucleotides and cysteinyl leukotrienes is considered as a crucial target for the neurodegenerative diseases. cysteinyl-leukotriene 122-144 G protein-coupled receptor 17 Homo sapiens 56-62 31742746-1 2020 Cysteinyl leukotrienes (CysLTs) are a group of eicosanoids that regulate the pathogenesis of various human diseases, mainly by signaling through the cysteinyl leukotriene receptor 1 (CysLTR1). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 149-181 2549655-1 1989 Using radioimmunoassay techniques we studied the formation of the 5-lipoxygenase-derived cysteinyl-leukotrienes (LT) in comparison to the cyclooxygenase product thromboxane (TX) B2 in whole human blood allowed to clot at 37 degrees C in vitro. cysteinyl-leukotriene 89-111 arachidonate 5-lipoxygenase Homo sapiens 66-80 33480040-2 2021 Blocking the Cysteinyl leukotrienes receptor (CysLTR1), one of the primary receptors of leukotrienes, has been demonstrated to be efficacious in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through disrupting chemotaxis of infiltrating T cells. cysteinyl-leukotriene 13-35 cysteinyl leukotriene receptor 1 Mus musculus 46-53 33542757-5 2021 Objective To evaluate the effects of the cysteinyl leukotriene (CysLT) receptor antagonist montelukast on the systemic production of TGF-beta1 in patients with nasal polyposis, with or without concomitant aspirin intolerance. cysteinyl-leukotriene 42-63 transforming growth factor beta 1 Homo sapiens 134-143 33542757-5 2021 Objective To evaluate the effects of the cysteinyl leukotriene (CysLT) receptor antagonist montelukast on the systemic production of TGF-beta1 in patients with nasal polyposis, with or without concomitant aspirin intolerance. cysteinyl-leukotriene 65-70 transforming growth factor beta 1 Homo sapiens 134-143 32032565-16 2020 Furthermore, leukotriene B4, cysteinyl-leukotrienes and 5-LOX expression in the cortical peri-infarct region of rats with focal cerebral I/R injury were also downregulated by miR-193b-3p agomir treatment but upregulated by miR-193b-3p antagomir. cysteinyl-leukotriene 13-51 microRNA 193b Rattus norvegicus 175-183 31560800-3 2020 His achievements include discovering and cloning the elusive leukotriene E4 receptor (1), isolating and cloning the enzyme leukotriene C4 synthase (LTC4S) responsible for the first committed step in the production of the cysLTs (2), and the derivation of its crystal structure (3). cysteinyl-leukotriene 221-227 leukotriene C4 synthase Homo sapiens 123-146 31560800-3 2020 His achievements include discovering and cloning the elusive leukotriene E4 receptor (1), isolating and cloning the enzyme leukotriene C4 synthase (LTC4S) responsible for the first committed step in the production of the cysLTs (2), and the derivation of its crystal structure (3). cysteinyl-leukotriene 221-227 leukotriene C4 synthase Homo sapiens 148-153 35152061-3 2022 Compound 10 and 49 also inhibited leukotriene C4 synthase (LTC4S) at sub-muM concentrations (IC50 = 0.7 and 0.4 muM, respectively), affording compounds dually targeting inflammatory PGE2 and cysteinyl leukotriene (cys-LT) biosynthesis. cysteinyl-leukotriene 191-212 leukotriene C4 synthase Homo sapiens 34-57 35152061-3 2022 Compound 10 and 49 also inhibited leukotriene C4 synthase (LTC4S) at sub-muM concentrations (IC50 = 0.7 and 0.4 muM, respectively), affording compounds dually targeting inflammatory PGE2 and cysteinyl leukotriene (cys-LT) biosynthesis. cysteinyl-leukotriene 191-212 leukotriene C4 synthase Homo sapiens 59-64 35152061-3 2022 Compound 10 and 49 also inhibited leukotriene C4 synthase (LTC4S) at sub-muM concentrations (IC50 = 0.7 and 0.4 muM, respectively), affording compounds dually targeting inflammatory PGE2 and cysteinyl leukotriene (cys-LT) biosynthesis. cysteinyl-leukotriene 214-220 leukotriene C4 synthase Homo sapiens 34-57 35152061-3 2022 Compound 10 and 49 also inhibited leukotriene C4 synthase (LTC4S) at sub-muM concentrations (IC50 = 0.7 and 0.4 muM, respectively), affording compounds dually targeting inflammatory PGE2 and cysteinyl leukotriene (cys-LT) biosynthesis. cysteinyl-leukotriene 214-220 leukotriene C4 synthase Homo sapiens 59-64 2717778-1 1989 In the isolated rat stomach perfused via the vasculature in situ under constant pressure bolus injections of platelet-activating factor (PAF, 3, 16, or 50 ng) induced dose-dependent, long-lasting reductions of flow rates and simultaneously significant increases in the release of cysteinyl-leukotrienes (cys-LT), thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1 alpha. cysteinyl-leukotriene 280-302 PCNA clamp associated factor Rattus norvegicus 109-135 2717778-1 1989 In the isolated rat stomach perfused via the vasculature in situ under constant pressure bolus injections of platelet-activating factor (PAF, 3, 16, or 50 ng) induced dose-dependent, long-lasting reductions of flow rates and simultaneously significant increases in the release of cysteinyl-leukotrienes (cys-LT), thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1 alpha. cysteinyl-leukotriene 280-302 PCNA clamp associated factor Rattus norvegicus 137-140 2717778-1 1989 In the isolated rat stomach perfused via the vasculature in situ under constant pressure bolus injections of platelet-activating factor (PAF, 3, 16, or 50 ng) induced dose-dependent, long-lasting reductions of flow rates and simultaneously significant increases in the release of cysteinyl-leukotrienes (cys-LT), thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1 alpha. cysteinyl-leukotriene 304-310 PCNA clamp associated factor Rattus norvegicus 109-135 2717778-1 1989 In the isolated rat stomach perfused via the vasculature in situ under constant pressure bolus injections of platelet-activating factor (PAF, 3, 16, or 50 ng) induced dose-dependent, long-lasting reductions of flow rates and simultaneously significant increases in the release of cysteinyl-leukotrienes (cys-LT), thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1 alpha. cysteinyl-leukotriene 304-310 PCNA clamp associated factor Rattus norvegicus 137-140 33955560-2 2021 NSAID-hypersensitivity is bred by cyclooxygenase (COX)-1 inhibition, which leads to an imbalance in prostaglandin (PG) and cysteinyl-leukotriene (CysLT) synthesis. cysteinyl-leukotriene 123-144 mitochondrially encoded cytochrome c oxidase I Homo sapiens 34-56 33955560-2 2021 NSAID-hypersensitivity is bred by cyclooxygenase (COX)-1 inhibition, which leads to an imbalance in prostaglandin (PG) and cysteinyl-leukotriene (CysLT) synthesis. cysteinyl-leukotriene 146-151 mitochondrially encoded cytochrome c oxidase I Homo sapiens 34-56 33287369-1 2020 Cysteinyl leukotriene G protein-coupled receptors, CysLT1R and CysLT2R, regulate bronchoconstrictive and pro-inflammatory effects and play a key role in allergic disorders, cardiovascular diseases, and cancer. cysteinyl-leukotriene 0-21 cysteinyl leukotriene receptor 1 Homo sapiens 51-58 33287369-1 2020 Cysteinyl leukotriene G protein-coupled receptors, CysLT1R and CysLT2R, regulate bronchoconstrictive and pro-inflammatory effects and play a key role in allergic disorders, cardiovascular diseases, and cancer. cysteinyl-leukotriene 0-21 cysteinyl leukotriene receptor 2 Homo sapiens 63-70 32881004-0 2020 Trichomonas vaginalis-secreted-cysteinyl leukotrienes promote migration, degranulation, and MCP-1 production in mast cells. cysteinyl-leukotriene 31-53 chemokine (C-C motif) ligand 2 Mus musculus 92-97 32948789-6 2020 The potently chemotactic chemokine CCL2 was induced by exosomes from a subgroup of patients, and in a blocking assay the exosome-induced CCL2 was reduced for 13 out of 19 patients by the asthma drug Montelukast, a cysteinyl leukotriene receptor antagonist. cysteinyl-leukotriene 214-235 C-C motif chemokine ligand 2 Homo sapiens 35-39 32948789-6 2020 The potently chemotactic chemokine CCL2 was induced by exosomes from a subgroup of patients, and in a blocking assay the exosome-induced CCL2 was reduced for 13 out of 19 patients by the asthma drug Montelukast, a cysteinyl leukotriene receptor antagonist. cysteinyl-leukotriene 214-235 C-C motif chemokine ligand 2 Homo sapiens 137-141 33336182-2 2020 Patients with AERD are dependent on COX-1 activity to maintain production of prostaglandin (PG) species, such as PGE2, which maintain physiologic levels of inflammation and limit the production of pro-inflammatory cysteinyl leukotrienes. cysteinyl-leukotriene 214-236 prostaglandin-endoperoxide synthase 1 Homo sapiens 36-41 32222525-0 2020 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer"s disease. cysteinyl-leukotriene 42-64 arachidonate 5-lipoxygenase Homo sapiens 0-14 32222525-1 2020 5-lipoxygenase (ALOX5) is an enzyme involved in arachidonic acid (AA) metabolism, a metabolic pathway in which cysteinyl leukotrienes (CysLTs) are the resultant metabolites. cysteinyl-leukotriene 111-133 arachidonate 5-lipoxygenase Homo sapiens 0-14 32222525-1 2020 5-lipoxygenase (ALOX5) is an enzyme involved in arachidonic acid (AA) metabolism, a metabolic pathway in which cysteinyl leukotrienes (CysLTs) are the resultant metabolites. cysteinyl-leukotriene 111-133 arachidonate 5-lipoxygenase Homo sapiens 16-21 32222525-1 2020 5-lipoxygenase (ALOX5) is an enzyme involved in arachidonic acid (AA) metabolism, a metabolic pathway in which cysteinyl leukotrienes (CysLTs) are the resultant metabolites. cysteinyl-leukotriene 135-141 arachidonate 5-lipoxygenase Homo sapiens 0-14 32222525-1 2020 5-lipoxygenase (ALOX5) is an enzyme involved in arachidonic acid (AA) metabolism, a metabolic pathway in which cysteinyl leukotrienes (CysLTs) are the resultant metabolites. cysteinyl-leukotriene 135-141 arachidonate 5-lipoxygenase Homo sapiens 16-21 32299856-2 2020 TRPV4 activation causes contraction of human ASM via the release of cysteinyl leukotrienes (cysLTs) but the mechanism is unknown. cysteinyl-leukotriene 68-90 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-5 32299856-2 2020 TRPV4 activation causes contraction of human ASM via the release of cysteinyl leukotrienes (cysLTs) but the mechanism is unknown. cysteinyl-leukotriene 68-90 H19 imprinted maternally expressed transcript Homo sapiens 45-48 32299856-2 2020 TRPV4 activation causes contraction of human ASM via the release of cysteinyl leukotrienes (cysLTs) but the mechanism is unknown. cysteinyl-leukotriene 92-98 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-5 32299856-2 2020 TRPV4 activation causes contraction of human ASM via the release of cysteinyl leukotrienes (cysLTs) but the mechanism is unknown. cysteinyl-leukotriene 92-98 H19 imprinted maternally expressed transcript Homo sapiens 45-48 31742746-1 2020 Cysteinyl leukotrienes (CysLTs) are a group of eicosanoids that regulate the pathogenesis of various human diseases, mainly by signaling through the cysteinyl leukotriene receptor 1 (CysLTR1). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 183-190 31742746-1 2020 Cysteinyl leukotrienes (CysLTs) are a group of eicosanoids that regulate the pathogenesis of various human diseases, mainly by signaling through the cysteinyl leukotriene receptor 1 (CysLTR1). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 149-181 31742746-1 2020 Cysteinyl leukotrienes (CysLTs) are a group of eicosanoids that regulate the pathogenesis of various human diseases, mainly by signaling through the cysteinyl leukotriene receptor 1 (CysLTR1). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 183-190 31742746-9 2020 Lastly, the responsiveness of cardiac muscle cells to CysLTs were significantly impaired by the L118F substitution in CysLTR1 proteins. cysteinyl-leukotriene 54-60 cysteinyl leukotriene receptor 1 Mus musculus 118-125 31552714-3 2019 Upon pharmacological inhibition of cyclooxygenase 1 by NSAIDs, production of anti-inflammatory prostaglandin E2 and lipoxins ceases, while release of proinflammatory cysteinyl leukotrienes increases. cysteinyl-leukotriene 166-188 prostaglandin-endoperoxide synthase 1 Homo sapiens 35-51 31986345-2 2020 Cysteinyl leukotrienes (CysLTs) are potent inflammatory lipid mediators that exhibit actions mainly through activating type 1 and type 2 CysLT receptors (CysLT1 and CysLT2). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 154-160 31986345-2 2020 Cysteinyl leukotrienes (CysLTs) are potent inflammatory lipid mediators that exhibit actions mainly through activating type 1 and type 2 CysLT receptors (CysLT1 and CysLT2). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 165-171 31986345-2 2020 Cysteinyl leukotrienes (CysLTs) are potent inflammatory lipid mediators that exhibit actions mainly through activating type 1 and type 2 CysLT receptors (CysLT1 and CysLT2). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 154-160 31986345-2 2020 Cysteinyl leukotrienes (CysLTs) are potent inflammatory lipid mediators that exhibit actions mainly through activating type 1 and type 2 CysLT receptors (CysLT1 and CysLT2). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Homo sapiens 165-171 31953256-0 2020 Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2. cysteinyl-leukotriene 28-50 purinergic receptor P2Y, G-protein coupled 2 Mus musculus 74-78 31953256-9 2020 ATP- and aeroallergen-elicited CysLT generation in the nasal lavage is reduced in mice lacking Pou2f3, a requisite transcription factor for BrC development. cysteinyl-leukotriene 31-36 POU domain, class 2, transcription factor 3 Mus musculus 95-101 31754028-8 2019 Gene expression analysis reveals erythroid and myeloid priming in the NEO1+ fraction and association of quiescence and self-renewal-related transcription factors with NEO1- LT-HSCs. cysteinyl-leukotriene 173-175 neogenin Mus musculus 167-171 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 36-38 neogenin Mus musculus 22-26 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 36-38 neogenin Mus musculus 60-64 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 36-38 homeobox B5 Mus musculus 66-71 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 36-38 neogenin Mus musculus 60-64 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 36-38 homeobox B5 Mus musculus 66-71 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 neogenin Mus musculus 22-26 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 homeobox B5 Mus musculus 28-33 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 neogenin Mus musculus 22-26 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 homeobox B5 Mus musculus 28-33 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 neogenin Mus musculus 22-26 31754028-9 2019 Finally, transplanted NEO1+ Hoxb5 + LT-HSCs rarely generate NEO1- Hoxb5 + LT-HSCs while NEO1- Hoxb5 + LT-HSCs repopulate both LT-HSC fractions. cysteinyl-leukotriene 74-76 homeobox B5 Mus musculus 28-33 31754028-10 2019 This supports a model in which dormant, balanced NEO1- Hoxb5 + LT-HSCs can hierarchically precede active, myeloid-biased NEO1+ Hoxb5 + LT-HSCs. cysteinyl-leukotriene 63-65 neogenin Mus musculus 49-53 31811124-1 2019 Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. cysteinyl-leukotriene 0-21 cysteinyl leukotriene receptor 1 Homo sapiens 50-56 31811124-1 2019 Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. cysteinyl-leukotriene 0-21 cysteinyl leukotriene receptor 2 Homo sapiens 61-67 31767622-7 2020 Leukotriene antagonists that block the signaling of cysteinyl leukotriene receptor 1 are used as an add-on therapy to reduce bronchoconstriction and inflammation induced by cysteinyl leukotrienes. cysteinyl-leukotriene 173-195 cysteinyl leukotriene receptor 1 Homo sapiens 52-84 31754028-4 2019 Here, we identify Neogenin-1 (NEO1) as a unique surface marker on a fraction of mouse HSCs labeled with Hoxb5, a specific reporter of long-term HSCs (LT-HSCs). cysteinyl-leukotriene 150-152 neogenin Mus musculus 18-28 31754028-4 2019 Here, we identify Neogenin-1 (NEO1) as a unique surface marker on a fraction of mouse HSCs labeled with Hoxb5, a specific reporter of long-term HSCs (LT-HSCs). cysteinyl-leukotriene 150-152 neogenin Mus musculus 30-34 31754028-4 2019 Here, we identify Neogenin-1 (NEO1) as a unique surface marker on a fraction of mouse HSCs labeled with Hoxb5, a specific reporter of long-term HSCs (LT-HSCs). cysteinyl-leukotriene 150-152 homeobox B5 Mus musculus 104-109 31754028-6 2019 Furthermore, NEO1+ Hoxb5 + LT-HSCs are more often in the G2/S cell cycle phase compared to NEO1- Hoxb5 + LT-HSCs in both young and old bone marrow. cysteinyl-leukotriene 27-29 neogenin Mus musculus 13-17 31638598-1 2019 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT1R) are widely used to treat asthma and allergic rhinitis, with variable response rates. cysteinyl-leukotriene 26-47 cysteinyl leukotriene receptor 1 Mus musculus 58-65 31633023-1 2019 The G protein-coupled cysteinyl leukotriene receptor CysLT1R mediates inflammatory processes and plays a major role in numerous disorders, including asthma, allergic rhinitis, cardiovascular disease, and cancer. cysteinyl-leukotriene 22-43 cysteinyl leukotriene receptor 1 Homo sapiens 53-60 31591069-4 2019 These molecules act as inflammatory mediators through different types of high-affinity receptors, namely, CysLT1, CysLT2, and CysLT3 (also named as GPR99). cysteinyl-leukotriene 126-132 oxoglutarate receptor 1 Homo sapiens 148-153 31415176-3 2019 Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade. cysteinyl-leukotriene 155-176 leukotriene C4 synthase Homo sapiens 25-48 31415176-3 2019 Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade. cysteinyl-leukotriene 155-176 leukotriene C4 synthase Homo sapiens 50-55 31220342-4 2019 We established that leptin, but not adiponectin, stimulates MCs to release of histamine as well as to generation of cysteinyl leukotrienes (cysLTs) and chemokine CCL2. cysteinyl-leukotriene 116-138 leptin Rattus norvegicus 20-26 29161055-1 2018 BACKGROUND: The cysteinyl leukotrienes (cysLTs) are proinflammatory lipid mediators that act on the type 1 cysLT receptor (CysLT1R) in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 1 Homo sapiens 123-130 30810163-6 2019 Chronic stress up-regulates hippocampal expression of 5-lipoxygenase, hence synthesis of cysteinyl leukotrienes, thereby inducing depression through their receptors. cysteinyl-leukotriene 89-111 arachidonate 5-lipoxygenase Homo sapiens 54-68 30389631-1 2019 Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase Homo sapiens 175-180 29696987-8 2018 In vivo, CRA-challenged FABP4-deficient mice exhibited attenuated eosinophilia and significantly reduced airway inflammation (improved airway reactivity, lower IL-5, IL-13, TNF-alpha, and cysteinyl leukotriene C4 levels, decreased airway structural changes) compared with WT mice. cysteinyl-leukotriene 188-209 fatty acid binding protein 4, adipocyte Mus musculus 24-29 30965222-6 2019 Several lines of evidence show that the enhancing effect of Myr requires functional integrity of the 5-lipoxygenase (5-LO) pathway, and of CysLT1 receptors, which transduce the effects of cysteinyl-leukotrienes generated through this pathway. cysteinyl-leukotriene 188-210 cysteinyl leukotriene receptor 1 Mus musculus 139-145 30389631-1 2019 Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 159-173 30389631-1 2019 Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 175-180 30389631-1 2019 Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase Homo sapiens 159-173 30226562-1 2018 GPR17 is a G (i)-coupled dual receptor, linked to P2Y and CysLT receptors stimulated by uracil nucleotides and cysteinyl leukotrienes, respectively. cysteinyl-leukotriene 111-133 G protein-coupled receptor 17 Homo sapiens 0-5 28965882-3 2018 Furthermore, when cysteinyl leukotriene (cysLT) and leukotriene (LTB4) receptors were antagonized in WT mice, there was a remarkable reduction in TNF-alpha expression and faster skin healing, similarly to the findings in 5-LO-/- animals. cysteinyl-leukotriene 18-39 tumor necrosis factor Mus musculus 146-155 29412178-4 2018 Cysteinyl leukotriene receptor 1 (cysLT1R) is an important G protein-coupled receptor mediating the biological functions of cysteinyl leukotrienes (cys-LTs). cysteinyl-leukotriene 124-146 cysteinyl leukotriene receptor 1 Mus musculus 0-32 29412178-4 2018 Cysteinyl leukotriene receptor 1 (cysLT1R) is an important G protein-coupled receptor mediating the biological functions of cysteinyl leukotrienes (cys-LTs). cysteinyl-leukotriene 124-146 cysteinyl leukotriene receptor 1 Mus musculus 34-41 29412178-4 2018 Cysteinyl leukotriene receptor 1 (cysLT1R) is an important G protein-coupled receptor mediating the biological functions of cysteinyl leukotrienes (cys-LTs). cysteinyl-leukotriene 148-155 cysteinyl leukotriene receptor 1 Mus musculus 0-32 29412178-4 2018 Cysteinyl leukotriene receptor 1 (cysLT1R) is an important G protein-coupled receptor mediating the biological functions of cysteinyl leukotrienes (cys-LTs). cysteinyl-leukotriene 148-155 cysteinyl leukotriene receptor 1 Mus musculus 34-41 29157985-6 2018 We confirmed the results of previous studies demonstrating a marked enhancement of mast cell mediator release following cyclooxygenase inhibition, but we have extended these results by showing that COX-2 derived eicosanoids inhibit cysteinyl-leukotriene release and yet are without effect on histamine release. cysteinyl-leukotriene 232-253 cytochrome c oxidase subunit II Cavia porcellus 198-203 28068410-3 2017 Recently, the mTOR pathway component p70S6 kinase 1 (p70S6K1) has been linked to LTC4 synthase and the biosynthesis of cysteinyl-leukotrienes. cysteinyl-leukotriene 119-141 mechanistic target of rapamycin kinase Homo sapiens 14-18 28550097-0 2017 Correction to "The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes". cysteinyl-leukotriene 83-105 G protein-coupled receptor 17 Homo sapiens 35-40 27888917-2 2017 The hallmark of the disease is baseline overproduction of cysteinyl leukotrienes via the 5-lipoxygenase pathway, exacerbated by ingestion of aspirin. cysteinyl-leukotriene 58-80 arachidonate 5-lipoxygenase Homo sapiens 89-103 28254957-0 2017 The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes. cysteinyl-leukotriene 68-90 G protein-coupled receptor 17 Homo sapiens 20-25 28261551-5 2017 We have further shown that cysteinyl-leukotrienes (CysLT), a major proinflammatory class of lipid mediators, generated through the 5-lipoxygenase pathway, upregulate bone-marrow eosinopoiesis in vivo and in vitro. cysteinyl-leukotriene 27-49 arachidonate 5-lipoxygenase Mus musculus 131-145 27810377-1 2017 Previously we reported that cysteinyl leukotrienes (Cys-LTs) and the type 1 receptor for Cys-LTs (CysLT1R) are related to amyloid beta (Abeta)-induced neurotoxicity. cysteinyl-leukotriene 28-50 cysteinyl leukotriene receptor 1 Mus musculus 98-105 27582398-9 2016 However, other abnormalities are also reported in this type of asthma as a resistance to anti-inflammatory activity of prostaglandin E2 or a robust eosinophil interferon-gamma response resulting in cysteinyl leukotrienes production. cysteinyl-leukotriene 198-220 interferon gamma Homo sapiens 159-175 28828731-1 2017 In 2006, cells heterologously expressing the "orphan" receptor GPR17 were shown to acquire responses to both uracil nucleotides and cysteinyl-leukotrienes, two families of signaling molecules accumulating in brain or heart as a result of hypoxic/traumatic injuries. cysteinyl-leukotriene 132-154 G protein-coupled receptor 17 Homo sapiens 63-68 27863043-1 2016 The GPR17 receptor is a G protein-coupled receptor (GPCR) that seems to respond to two unrelated families of endogenous ligands: nucleotide sugars (UDP, UDP-galactose, and UDP-glucose) and cysteinyl leukotrienes (LTD4 , LTC4 , and LTE4 ), with significant affinity at micromolar and nanomolar concentrations, respectively. cysteinyl-leukotriene 189-211 G protein-coupled receptor 17 Homo sapiens 4-9 28932020-1 2017 Cysteinyl leukotrienes (CysLTs) are potent lipid inflammatory mediators synthesized from arachidonic acid, through the 5-lipoxygenase (5-LO) pathway. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 119-133 28932020-1 2017 Cysteinyl leukotrienes (CysLTs) are potent lipid inflammatory mediators synthesized from arachidonic acid, through the 5-lipoxygenase (5-LO) pathway. cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase Homo sapiens 119-133 25579761-5 2015 In particular, it was shown that the platelet P2Y12 receptor for ADP significantly contributed to the pro-inflammatory effects of cysteinyl leukotrienes (CysLT) in experimental models of asthma in mice. cysteinyl-leukotriene 130-152 purinergic receptor P2Y12 Homo sapiens 46-51 27791009-8 2016 Of note, both GSTM4 and GGT enzymes displayed higher affinity to 13S,14S-eMaR and MCTR1 compared with their classic substrates in the cysteinyl leukotriene metabolome. cysteinyl-leukotriene 134-155 glutathione S-transferase mu 4 Homo sapiens 14-19 27226094-1 2016 The bronchoconstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma mediate their effects predominantly through the cysLT1 receptor (cysLT1R). cysteinyl-leukotriene 58-80 cysteinyl leukotriene receptor 1 Mus musculus 157-172 27226094-1 2016 The bronchoconstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma mediate their effects predominantly through the cysLT1 receptor (cysLT1R). cysteinyl-leukotriene 58-80 cysteinyl leukotriene receptor 1 Mus musculus 174-181 27226094-1 2016 The bronchoconstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma mediate their effects predominantly through the cysLT1 receptor (cysLT1R). cysteinyl-leukotriene 82-88 cysteinyl leukotriene receptor 1 Mus musculus 157-172 27226094-1 2016 The bronchoconstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma mediate their effects predominantly through the cysLT1 receptor (cysLT1R). cysteinyl-leukotriene 82-88 cysteinyl leukotriene receptor 1 Mus musculus 174-181 26139511-0 2016 Endogenous secreted phospholipase A2 group X regulates cysteinyl leukotrienes synthesis by human eosinophils. cysteinyl-leukotriene 55-77 phospholipase A2 group IB Homo sapiens 20-36 26139511-1 2016 BACKGROUND: Phospholipase A2s mediate the rate-limiting step in the formation of eicosanoids such as cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 101-123 phospholipase A2 group IB Homo sapiens 12-28 26139511-1 2016 BACKGROUND: Phospholipase A2s mediate the rate-limiting step in the formation of eicosanoids such as cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 125-131 phospholipase A2 group IB Homo sapiens 12-28 26363927-6 2015 Fat-1 BMMC released less beta-hexosaminidase (beta-hex) and cysteinyl leukotrienes and produced less tumor necrosis factor and chemokine (C-C motif) ligand 2. n-3 PUFA supplementation reduced LAD2 and BMMC degranulation (beta-hex release) following FcepsilonRI activation. cysteinyl-leukotriene 60-82 FAT atypical cadherin 1 Mus musculus 0-5 26283693-2 2015 The enzyme catalyzing synthesis of cys-LTs, leukotriene C4 synthase (LTC4S), is considered an important drug target. cysteinyl-leukotriene 35-42 leukotriene C4 synthase Homo sapiens 44-67 26283693-2 2015 The enzyme catalyzing synthesis of cys-LTs, leukotriene C4 synthase (LTC4S), is considered an important drug target. cysteinyl-leukotriene 35-42 leukotriene C4 synthase Homo sapiens 69-74 26304964-0 2015 Cysteinyl leukotrienes mediate lymphokine killer activity induced by NKG2D and IL-15 in cytotoxic T cells during celiac disease. cysteinyl-leukotriene 0-22 killer cell lectin like receptor K1 Homo sapiens 69-74 26304964-0 2015 Cysteinyl leukotrienes mediate lymphokine killer activity induced by NKG2D and IL-15 in cytotoxic T cells during celiac disease. cysteinyl-leukotriene 0-22 interleukin 15 Homo sapiens 79-84 25839425-0 2015 Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT2 receptor. cysteinyl-leukotriene 22-44 cysteinyl leukotriene receptor 2 Homo sapiens 104-110 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 208-214 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 225-232 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 238-244 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 255-262 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 208-214 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 225-232 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Homo sapiens 238-244 25866815-1 2015 Cysteinyl leukotrienes (cysLTs) are cell membrane-impermeant lipid mediators that play major roles in the pathogenesis of eosinophilic inflammation and are recognized to act via at least 2 receptors, namely, cysLT1 receptor (cysLT1R) and cysLT2 receptor (cysLT2R). cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Homo sapiens 255-262 27712766-1 2016 Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes. cysteinyl-leukotriene 207-229 arachidonate 5-lipoxygenase Homo sapiens 111-125 27712766-1 2016 Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes. cysteinyl-leukotriene 207-229 leukotriene C4 synthase Homo sapiens 130-153 27712766-1 2016 Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes. cysteinyl-leukotriene 207-229 leukotriene C4 synthase Homo sapiens 155-160 27423494-2 2016 We have previously demonstrated the capacity of IFN-gamma to drive cysteinyl leukotriene expression and response. cysteinyl-leukotriene 67-88 interferon gamma Homo sapiens 48-57 27194783-5 2016 Inhibition of PI3Kdelta also reduces cysteinyl leukotrienes and cytokines elicited by Dectin-2 cross-linking, confirming the importance of this molecule in Dectin-2 signaling. cysteinyl-leukotriene 37-59 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Mus musculus 14-23 26971834-1 2016 Recent data and publications suggest a promiscuous behaviour for GPR17, a class-A GPCR operated by different classes of ligands, such as uracil nucleotides, cysteinyl-leukotrienes and oxysterols. cysteinyl-leukotriene 157-179 G protein-coupled receptor 17 Homo sapiens 65-70 26971834-1 2016 Recent data and publications suggest a promiscuous behaviour for GPR17, a class-A GPCR operated by different classes of ligands, such as uracil nucleotides, cysteinyl-leukotrienes and oxysterols. cysteinyl-leukotriene 157-179 G protein-coupled receptor 166 pseudogene Homo sapiens 82-86 26869085-1 2016 Cysteinyl-leukotrienes are pro-inflammatory lipid mediators, involved in allergic asthma, that bind the G-protein-coupled receptors CysLT1, CysLT2 and GPR99. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 132-138 26869085-1 2016 Cysteinyl-leukotrienes are pro-inflammatory lipid mediators, involved in allergic asthma, that bind the G-protein-coupled receptors CysLT1, CysLT2 and GPR99. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 140-146 26869085-1 2016 Cysteinyl-leukotrienes are pro-inflammatory lipid mediators, involved in allergic asthma, that bind the G-protein-coupled receptors CysLT1, CysLT2 and GPR99. cysteinyl-leukotriene 0-22 oxoglutarate receptor 1 Homo sapiens 151-156 25962903-10 2015 Measurement of the release of histamine and cysteinyl leukotrienes documented that this bronchoprotective action of PGE2 was mediated by the EP2 receptor, unrelated to bronchodilation, and increased with time of exposure. cysteinyl-leukotriene 44-66 prostaglandin E receptor 2 Homo sapiens 141-144 26342029-0 2015 Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway. cysteinyl-leukotriene 51-72 interleukin 33 Mus musculus 80-85 26020772-10 2015 In addition, the vascular endothelial growth factor (VEGF) level was increased in the nasal lavage fluid of asthmatics and there were positive correlations between FABP5 and VEGF levels (r=0.660, p<0.001) and concentrations of FABP5 and cysteinyl leukotriene (CysLT) (r=0.535, p<0.001) in the nasal lavage fluid. cysteinyl-leukotriene 240-261 vascular endothelial growth factor A Homo sapiens 17-51 26020772-10 2015 In addition, the vascular endothelial growth factor (VEGF) level was increased in the nasal lavage fluid of asthmatics and there were positive correlations between FABP5 and VEGF levels (r=0.660, p<0.001) and concentrations of FABP5 and cysteinyl leukotriene (CysLT) (r=0.535, p<0.001) in the nasal lavage fluid. cysteinyl-leukotriene 240-261 vascular endothelial growth factor A Homo sapiens 53-57 26020772-10 2015 In addition, the vascular endothelial growth factor (VEGF) level was increased in the nasal lavage fluid of asthmatics and there were positive correlations between FABP5 and VEGF levels (r=0.660, p<0.001) and concentrations of FABP5 and cysteinyl leukotriene (CysLT) (r=0.535, p<0.001) in the nasal lavage fluid. cysteinyl-leukotriene 240-261 fatty acid binding protein 5 Homo sapiens 164-169 25161061-2 2015 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory mediators that signal through CysLT1 R and CysLT2 R located on the MC surface, and they enhance MC inflammatory responses. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 87-95 25161061-2 2015 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory mediators that signal through CysLT1 R and CysLT2 R located on the MC surface, and they enhance MC inflammatory responses. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 100-108 25161061-2 2015 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory mediators that signal through CysLT1 R and CysLT2 R located on the MC surface, and they enhance MC inflammatory responses. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 1 Homo sapiens 87-95 25161061-2 2015 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory mediators that signal through CysLT1 R and CysLT2 R located on the MC surface, and they enhance MC inflammatory responses. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 2 Homo sapiens 100-108 25590316-1 2015 BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. cysteinyl-leukotriene 197-219 arachidonate 5-lipoxygenase Homo sapiens 101-115 25590316-1 2015 BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. cysteinyl-leukotriene 197-219 leukotriene C4 synthase Homo sapiens 120-143 25590316-1 2015 BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. cysteinyl-leukotriene 197-219 leukotriene C4 synthase Homo sapiens 145-150 24858057-1 2014 The 5-lipoxygenase (5-LOX) products cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators. cysteinyl-leukotriene 36-58 arachidonate 5-lipoxygenase Rattus norvegicus 4-18 25624848-9 2014 CONCLUSIONS: The NALF concentrations of cys-LTs and 8-isoprostane change simultaneously with TNS-4 and nasal eosinophilia. cysteinyl-leukotriene 40-47 tensin 4 Homo sapiens 93-98 24990383-0 2014 Cathelicidin rCRAMP stimulates rat mast cells to generate cysteinyl leukotrienes, synthesize TNF and migrate: involvement of PLC/A2, PI3K and MAPK signaling pathways. cysteinyl-leukotriene 58-80 cathelicidin antimicrobial peptide Rattus norvegicus 13-19 24990383-4 2014 We have demonstrated that activation of fully mature rat mast cells with rCRAMP resulted in generation and release of cysteinyl leukotrienes (cysLTs). cysteinyl-leukotriene 118-140 cathelicidin antimicrobial peptide Rattus norvegicus 73-79 24909956-1 2014 GPR17 is a G(i) -coupled dual receptor activated by uracil-nucleotides and cysteinyl-leukotrienes. cysteinyl-leukotriene 75-97 G protein-coupled receptor 17 Mus musculus 0-5 24974917-2 2014 Leukotriene C4 synthase (LTC4S) is a nuclear-membrane enzyme responsible for the conjugation of leukotriene A4 (LTA4) to glutathione to form LTC4, a cysteinyl leukotriene. cysteinyl-leukotriene 149-170 leukotriene C4 synthase Homo sapiens 0-23 24974917-2 2014 Leukotriene C4 synthase (LTC4S) is a nuclear-membrane enzyme responsible for the conjugation of leukotriene A4 (LTA4) to glutathione to form LTC4, a cysteinyl leukotriene. cysteinyl-leukotriene 149-170 leukotriene C4 synthase Homo sapiens 25-30 24858057-1 2014 The 5-lipoxygenase (5-LOX) products cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators. cysteinyl-leukotriene 36-58 arachidonate 5-lipoxygenase Rattus norvegicus 20-25 24858057-1 2014 The 5-lipoxygenase (5-LOX) products cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators. cysteinyl-leukotriene 60-66 arachidonate 5-lipoxygenase Rattus norvegicus 4-18 24858057-1 2014 The 5-lipoxygenase (5-LOX) products cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators. cysteinyl-leukotriene 60-66 arachidonate 5-lipoxygenase Rattus norvegicus 20-25 24956889-9 2014 TLR7-mediated mast cell stimulation resulted in cysteinyl leukotriene (cysLT) and interferon (IFN)-beta synthesis, whereas no histamine and CXCL8 secretion was stated. cysteinyl-leukotriene 48-69 toll-like receptor 7 Rattus norvegicus 0-4 24991451-1 2014 Cysteinyl leukotrienes (cys-LTs) are potent mediators of inflammation derived from arachidonic acid through the 5-lipoxygenase/leukotriene C4 synthase pathway. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 112-126 24991451-1 2014 Cysteinyl leukotrienes (cys-LTs) are potent mediators of inflammation derived from arachidonic acid through the 5-lipoxygenase/leukotriene C4 synthase pathway. cysteinyl-leukotriene 0-22 leukotriene C4 synthase Homo sapiens 127-150 24991451-1 2014 Cysteinyl leukotrienes (cys-LTs) are potent mediators of inflammation derived from arachidonic acid through the 5-lipoxygenase/leukotriene C4 synthase pathway. cysteinyl-leukotriene 24-31 arachidonate 5-lipoxygenase Homo sapiens 112-126 24991451-1 2014 Cysteinyl leukotrienes (cys-LTs) are potent mediators of inflammation derived from arachidonic acid through the 5-lipoxygenase/leukotriene C4 synthase pathway. cysteinyl-leukotriene 24-31 leukotriene C4 synthase Homo sapiens 127-150 24220317-11 2014 Thymic stromal lymphopoietin combined with IL-33 increased tryptase and carboxypeptidase A3 immunostaining in mast cell precursors and selectively increased cysteinyl leukotriene formation by mast cells in a manner that was independent of in vitro sensitization. cysteinyl-leukotriene 157-178 interleukin 33 Homo sapiens 43-48 24129160-5 2014 Interestingly, cysteinyl leukotrienes, but not chemokine and cytokine levels were inhibited by anti-Dectin-2 in this acute model, and in ex vivo challenge of cultured alveolar macrophages with HDM. cysteinyl-leukotriene 15-37 C-type lectin domain family 4, member n Mus musculus 100-108 24129160-7 2014 Together these data suggest alveolar macrophage sensing of HDM by Dectin-2 elicits the production of cysteinyl leukotrienes, and this axis is key for the initiation of airway inflammation to this aeroallergen. cysteinyl-leukotriene 101-123 C-type lectin domain family 4, member n Mus musculus 66-74 24453247-1 2014 The myeloid C-type lectin receptor Dectin-2 directs the generation of Th2 and Th17 immune responses to the house dust mite Dermatophagoides farinae through the generation of cysteinyl leukotrienes and proinflammatory cytokines, respectively, but a role for Dectin-2 in effector phase responses has not been described. cysteinyl-leukotriene 174-196 C-type lectin domain family 4, member n Mus musculus 35-43 24504097-0 2014 Transient receptor potential vanilloid 4 activation constricts the human bronchus via the release of cysteinyl leukotrienes. cysteinyl-leukotriene 101-123 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-40 24504097-7 2014 Rather, we provide pharmacological evidence that TRPV4 activation causes human airway constriction that is entirely dependent upon the production of cysteinyl leukotrienes. cysteinyl-leukotriene 149-171 transient receptor potential cation channel subfamily V member 4 Homo sapiens 49-54 24366866-1 2014 Leukotriene (LT) C4 synthase (LTC4S) catalyzes the conjugation of the fatty acid LTA4 with the tripeptide GSH to produce LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma. cysteinyl-leukotriene 154-176 leukotriene C4 synthase Homo sapiens 0-28 24366866-1 2014 Leukotriene (LT) C4 synthase (LTC4S) catalyzes the conjugation of the fatty acid LTA4 with the tripeptide GSH to produce LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma. cysteinyl-leukotriene 154-176 leukotriene C4 synthase Homo sapiens 30-35 24050699-2 2014 It is now established that MRP1 plays a role in protecting certain tissues from xenobiotic insults and that it mediates the cellular efflux of the proinflammatory cysteinyl leukotriene C4 as well as a vast array of other endo- and xenobiotic organic anions. cysteinyl-leukotriene 163-184 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 24150253-4 2013 One of these, MDL29951, was carried forward to illustrate GPR17-dependent activation of Galphai- and Galphaq-promoted signaling pathways in cell lines expressing recombinant GPR17, whereas no effect was observed with previously proposed but dubitable agonists (uracil nucleotides and cysteinyl leukotrienes) of this receptor. cysteinyl-leukotriene 284-306 G protein-coupled receptor 17 Mus musculus 58-63 25150871-8 2014 In this chapter, pharmacogenetic and genomic studies on GPCR variants are reviewed with respect to a subset of GPCR systems, including the adrenergic, calcium sensing, cysteinyl leukotriene, cannabinoid CB1 and CB2 receptors, and the de-orphanized receptors such as GPR55. cysteinyl-leukotriene 168-189 G protein-coupled receptor 166 pseudogene Homo sapiens 56-60 25150871-8 2014 In this chapter, pharmacogenetic and genomic studies on GPCR variants are reviewed with respect to a subset of GPCR systems, including the adrenergic, calcium sensing, cysteinyl leukotriene, cannabinoid CB1 and CB2 receptors, and the de-orphanized receptors such as GPR55. cysteinyl-leukotriene 168-189 G protein-coupled receptor 166 pseudogene Homo sapiens 111-115 24253666-0 2013 Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 96-102 24253666-0 2013 Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 107-113 24253666-1 2013 Cysteinyl leukotrienes (cys-LTs), LTC4, LTD4, LTE4 are potent inflammatory lipid mediators that act through two distinct G-protein-coupled receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 150-157 24253666-1 2013 Cysteinyl leukotrienes (cys-LTs), LTC4, LTD4, LTE4 are potent inflammatory lipid mediators that act through two distinct G-protein-coupled receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 162-169 24253666-1 2013 Cysteinyl leukotrienes (cys-LTs), LTC4, LTD4, LTE4 are potent inflammatory lipid mediators that act through two distinct G-protein-coupled receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 1 Homo sapiens 150-157 24253666-1 2013 Cysteinyl leukotrienes (cys-LTs), LTC4, LTD4, LTE4 are potent inflammatory lipid mediators that act through two distinct G-protein-coupled receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 2 Homo sapiens 162-169 24253666-3 2013 Here, we show that cys-LTs (LTC4 and LTD4) induce robust calcium influx in human umbilical vein endothelial cells (HUVECs) through CysLT2R, but not CysLT1R. cysteinyl-leukotriene 19-26 cysteinyl leukotriene receptor 2 Homo sapiens 131-138 24253666-4 2013 Further, cys-LT treatment induced endothelial cell (EC) contraction leading to monolayer disruption via CysLT2R/Rho kinase dependent pathway. cysteinyl-leukotriene 9-15 cysteinyl leukotriene receptor 2 Homo sapiens 104-111 24253666-5 2013 Furthermore, stimulation with cys-LTs potentiated TNFalpha-induced VCAM-1 expression and leukocyte recruitment to ECs through CysLT2R. cysteinyl-leukotriene 30-37 tumor necrosis factor Homo sapiens 50-58 24253666-5 2013 Furthermore, stimulation with cys-LTs potentiated TNFalpha-induced VCAM-1 expression and leukocyte recruitment to ECs through CysLT2R. cysteinyl-leukotriene 30-37 vascular cell adhesion molecule 1 Homo sapiens 67-73 24253666-5 2013 Furthermore, stimulation with cys-LTs potentiated TNFalpha-induced VCAM-1 expression and leukocyte recruitment to ECs through CysLT2R. cysteinyl-leukotriene 30-37 cysteinyl leukotriene receptor 2 Homo sapiens 126-133 24253666-7 2013 Taken together, these results suggest that cys-LTs induce endothelial inflammation and proliferation via CysLT2R/Rho kinase and CysLT1R/Erk dependent pathways, respectively, which play critical role in the etiology of cardiovascular diseases such as atherosclerosis and myocardial infarction. cysteinyl-leukotriene 43-50 cysteinyl leukotriene receptor 2 Homo sapiens 105-112 24253666-7 2013 Taken together, these results suggest that cys-LTs induce endothelial inflammation and proliferation via CysLT2R/Rho kinase and CysLT1R/Erk dependent pathways, respectively, which play critical role in the etiology of cardiovascular diseases such as atherosclerosis and myocardial infarction. cysteinyl-leukotriene 43-50 cysteinyl leukotriene receptor 1 Homo sapiens 128-135 24253666-7 2013 Taken together, these results suggest that cys-LTs induce endothelial inflammation and proliferation via CysLT2R/Rho kinase and CysLT1R/Erk dependent pathways, respectively, which play critical role in the etiology of cardiovascular diseases such as atherosclerosis and myocardial infarction. cysteinyl-leukotriene 43-50 mitogen-activated protein kinase 1 Homo sapiens 136-139 24150253-4 2013 One of these, MDL29951, was carried forward to illustrate GPR17-dependent activation of Galphai- and Galphaq-promoted signaling pathways in cell lines expressing recombinant GPR17, whereas no effect was observed with previously proposed but dubitable agonists (uracil nucleotides and cysteinyl leukotrienes) of this receptor. cysteinyl-leukotriene 284-306 guanine nucleotide binding protein, alpha q polypeptide Mus musculus 101-108 23908386-1 2013 examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17. cysteinyl-leukotriene 58-80 uracil nucleotide/cysteinyl leukotriene receptor Cricetulus griseus 96-101 23908386-2 2013 The orphan receptor GPR17 has been reported to be activated by UDP, UDP-sugars, and cysteinyl leukotrienes, and coupled to intracellular Ca(2+) mobilization and inhibition of cAMP accumulation, but other studies have reported either a different agonist profile or lack of agonist activity altogether. cysteinyl-leukotriene 84-106 uracil nucleotide/cysteinyl leukotriene receptor Cricetulus griseus 20-25 23750020-1 2013 The cysteinyl leukotrienes (CysLTs) are inflammatory mediators closely associated with neuronal injury after brain ischemia through the activation of their receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Homo sapiens 167-174 23822826-1 2013 Leukotrienes (LTs) C4, D4, and E4, collectively termed cysteinyl LTs (cysLTs), are lipid mediators formed by the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. cysteinyl-leukotriene 55-68 arachidonate 5-lipoxygenase Homo sapiens 113-127 23822826-1 2013 Leukotrienes (LTs) C4, D4, and E4, collectively termed cysteinyl LTs (cysLTs), are lipid mediators formed by the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. cysteinyl-leukotriene 70-76 arachidonate 5-lipoxygenase Homo sapiens 113-127 23977066-7 2013 Interestingly, cys-LTs activated both PKCalpha and PKCepsilon isoforms in MC. cysteinyl-leukotriene 15-22 protein kinase C alpha Homo sapiens 38-46 23977066-7 2013 Interestingly, cys-LTs activated both PKCalpha and PKCepsilon isoforms in MC. cysteinyl-leukotriene 15-22 protein kinase C epsilon Homo sapiens 51-61 23750020-1 2013 The cysteinyl leukotrienes (CysLTs) are inflammatory mediators closely associated with neuronal injury after brain ischemia through the activation of their receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 2 Homo sapiens 179-186 23750020-1 2013 The cysteinyl leukotrienes (CysLTs) are inflammatory mediators closely associated with neuronal injury after brain ischemia through the activation of their receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 1 Homo sapiens 167-174 23750020-1 2013 The cysteinyl leukotrienes (CysLTs) are inflammatory mediators closely associated with neuronal injury after brain ischemia through the activation of their receptors, CysLT1R and CysLT2R. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 2 Homo sapiens 179-186 23246457-7 2013 This relives the inhibitory effect of PGE2 on 5-lipoxygenase (5-LOX) resulting in overproduction of cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 100-122 arachidonate 5-lipoxygenase Homo sapiens 46-60 23688412-1 2013 BACKGROUND: Cysteinyl leukotrienes (CysLTs) contribute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R). cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Mus musculus 95-127 23688412-1 2013 BACKGROUND: Cysteinyl leukotrienes (CysLTs) contribute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R). cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Mus musculus 129-136 23688412-1 2013 BACKGROUND: Cysteinyl leukotrienes (CysLTs) contribute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R). cysteinyl-leukotriene 36-42 cysteinyl leukotriene receptor 1 Mus musculus 95-127 23688412-1 2013 BACKGROUND: Cysteinyl leukotrienes (CysLTs) contribute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R). cysteinyl-leukotriene 36-42 cysteinyl leukotriene receptor 1 Mus musculus 129-136 23600541-3 2013 OBJECTIVE: We sought to determine if the ALOX5 promoter SP1 tandem repeat polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway inflammation and asthma control score. cysteinyl-leukotriene 118-139 arachidonate 5-lipoxygenase Homo sapiens 41-46 23246457-7 2013 This relives the inhibitory effect of PGE2 on 5-lipoxygenase (5-LOX) resulting in overproduction of cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 100-122 arachidonate 5-lipoxygenase Homo sapiens 62-67 23330796-0 2013 The antimicrobial peptide LL-37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils--implications for asthma. cysteinyl-leukotriene 65-87 cathelicidin antimicrobial peptide Homo sapiens 26-31 23639712-3 2013 The pathogenesis of these exacerbations is related to the inhibition of cyclooxygenase-1 leading to a decreased synthesis of PGE2 and an increased cysteinyl leukotriene production in the skin and subcutaneous tissues. cysteinyl-leukotriene 147-168 prostaglandin-endoperoxide synthase 1 Homo sapiens 72-88 23330796-9 2013 RESULTS: LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils. cysteinyl-leukotriene 80-102 cathelicidin antimicrobial peptide Homo sapiens 9-14 23330796-9 2013 RESULTS: LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils. cysteinyl-leukotriene 80-102 formyl peptide receptor 2 Homo sapiens 47-52 23330796-9 2013 RESULTS: LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils. cysteinyl-leukotriene 104-111 cathelicidin antimicrobial peptide Homo sapiens 9-14 23330796-9 2013 RESULTS: LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils. cysteinyl-leukotriene 104-111 formyl peptide receptor 2 Homo sapiens 47-52 23288840-1 2013 GPR17 is a G-protein-coupled receptor that is activated by two classes of molecules: uracil-nucleotides and cysteinyl-leukotrienes. cysteinyl-leukotriene 108-130 G protein-coupled receptor 17 Homo sapiens 0-5 23278880-10 2013 Similarly, SCF (100 ng/mL) alone was effective in stimulating the generation of cys-LTs in half of the preparations studied. cysteinyl-leukotriene 80-87 KIT ligand Homo sapiens 11-14 23505108-0 2013 [Expression and distribution of cysteinyl leukotriene receptors CysLT1R and CysLT2R, and GPR17 in brain of Parkinson disease model mice]. cysteinyl-leukotriene 32-53 cysteinyl leukotriene receptor 1 Mus musculus 64-71 23472176-3 2013 The aim of the study was to characterise the responsiveness of human P2Y12 to cysteinyl leukotrienes. cysteinyl-leukotriene 78-100 purinergic receptor P2Y12 Homo sapiens 69-74 23505108-0 2013 [Expression and distribution of cysteinyl leukotriene receptors CysLT1R and CysLT2R, and GPR17 in brain of Parkinson disease model mice]. cysteinyl-leukotriene 32-53 cysteinyl leukotriene receptor 2 Mus musculus 76-83 22420309-5 2012 However, no drugs have yet been developed targeting leukotriene C4 synthase, a key enzyme leading to the synthesis of cysteinyl leukotrienes. cysteinyl-leukotriene 118-140 leukotriene C4 synthase Homo sapiens 52-75 23002438-1 2012 Cysteinyl leukotrienes (cys-LTs) can mediate Th2 immunity to the house dust mite, Dermatophagoides farinae, via the type 1 receptor CysLT(1)R on dendritic cells (DCs). cysteinyl-leukotriene 0-22 heart and neural crest derivatives expressed 2 Mus musculus 45-48 23002438-1 2012 Cysteinyl leukotrienes (cys-LTs) can mediate Th2 immunity to the house dust mite, Dermatophagoides farinae, via the type 1 receptor CysLT(1)R on dendritic cells (DCs). cysteinyl-leukotriene 24-31 heart and neural crest derivatives expressed 2 Mus musculus 45-48 23109727-1 2012 5-Lipoxygenase (5-LO) catalyzes the formation of two major groups of leukotrienes, leukotriene B4 and cysteinyl leukotrienes (CysLTs), and it has been implicated as a promising drug target to treat various inflammatory diseases. cysteinyl-leukotriene 102-124 arachidonate 5-lipoxygenase Mus musculus 0-14 22316690-0 2012 Cysteinyl leukotrienes regulate TGF-beta(1) and collagen production by bronchial fibroblasts obtained from asthmatic subjects. cysteinyl-leukotriene 0-22 transforming growth factor beta 1 Homo sapiens 32-43 22541406-8 2012 IL-17A-deficient mice also showed decreased histamine and cysteinyl leukotriene release. cysteinyl-leukotriene 58-79 interleukin 17A Mus musculus 0-6 21936770-4 2012 Similar to the CXCR4 ligand CXCL12, the cysteinyl leukotriene (cysLT) LTD(4) induces calcium fluxes, actin polymerization, and chemotaxis. cysteinyl-leukotriene 40-61 C-X-C motif chemokine ligand 12 Homo sapiens 28-34 22391114-0 2012 Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. cysteinyl-leukotriene 29-51 cysteinyl leukotriene receptor 1 Homo sapiens 84-116 22155652-1 2012 G protein-coupled receptor 17 (GPR17), the new P2Y-like receptor, is phylogenetically related to the P2Y and cysteinyl leukotriene receptors, and responds to both uracil nucleotides and cysteinyl leukotrienes. cysteinyl-leukotriene 186-208 G protein-coupled receptor 17 Rattus norvegicus 0-29 22286339-7 2012 The second class is an inhibitor of the 5-lipoxygenase enzyme that prevents synthesis of both the cysteinyl leukotrienes and leukotriene B(4). cysteinyl-leukotriene 98-120 arachidonate 5-lipoxygenase Homo sapiens 40-54 22266348-0 2012 A geranyl acetophenone targeting cysteinyl leukotriene synthesis prevents allergic airway inflammation in ovalbumin-sensitized mice. cysteinyl-leukotriene 33-54 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 106-115 22217203-1 2012 Human leukotriene C4 synthase (hLTC4S) is an integral membrane protein that catalyzes the committed step in the biosynthesis of cysteinyl-leukotrienes, i.e., formation of leukotriene C4 (LTC4). cysteinyl-leukotriene 128-150 leukotriene C4 synthase Homo sapiens 6-29 22217203-1 2012 Human leukotriene C4 synthase (hLTC4S) is an integral membrane protein that catalyzes the committed step in the biosynthesis of cysteinyl-leukotrienes, i.e., formation of leukotriene C4 (LTC4). cysteinyl-leukotriene 128-150 leukotriene C4 synthase Homo sapiens 31-37 22155652-1 2012 G protein-coupled receptor 17 (GPR17), the new P2Y-like receptor, is phylogenetically related to the P2Y and cysteinyl leukotriene receptors, and responds to both uracil nucleotides and cysteinyl leukotrienes. cysteinyl-leukotriene 186-208 G protein-coupled receptor 17 Rattus norvegicus 31-36 22121385-0 2012 Interleukin-13, but not indomethacin, increases cysteinyl-leukotriene synthesis in human lung macrophages. cysteinyl-leukotriene 48-69 interleukin 13 Homo sapiens 0-14 22121385-3 2012 Overnight culture of human lung macrophages with IL-13 (10 ng/mL) increased spontaneous and ionophore-stimulated production of cysteinyl-leukotrienes by 42% (P = 0.02) and 52% (P = 0.005), respectively, as quantified by enzyme immunoassays, but PCR gene transcription assays did not demonstrate an effect on LTC4S mRNA. cysteinyl-leukotriene 127-149 interleukin 13 Homo sapiens 49-54 22829846-3 2012 While it has been long established that NSAIDs cause inhibition of cyclooxygenase-1 (COX-1), leading to excessive metabolism of arachidonic acid (AA) to cysteinyl-leukotrienes (cys-LTs), there is now evidence that both cytokines and staphylococcus superantigens amplify the inflammatory process exacerbating the disease. cysteinyl-leukotriene 153-175 prostaglandin-endoperoxide synthase 1 Homo sapiens 67-83 22121385-3 2012 Overnight culture of human lung macrophages with IL-13 (10 ng/mL) increased spontaneous and ionophore-stimulated production of cysteinyl-leukotrienes by 42% (P = 0.02) and 52% (P = 0.005), respectively, as quantified by enzyme immunoassays, but PCR gene transcription assays did not demonstrate an effect on LTC4S mRNA. cysteinyl-leukotriene 127-149 leukotriene C4 synthase Homo sapiens 308-313 22829846-3 2012 While it has been long established that NSAIDs cause inhibition of cyclooxygenase-1 (COX-1), leading to excessive metabolism of arachidonic acid (AA) to cysteinyl-leukotrienes (cys-LTs), there is now evidence that both cytokines and staphylococcus superantigens amplify the inflammatory process exacerbating the disease. cysteinyl-leukotriene 153-175 prostaglandin-endoperoxide synthase 1 Homo sapiens 85-90 22829846-3 2012 While it has been long established that NSAIDs cause inhibition of cyclooxygenase-1 (COX-1), leading to excessive metabolism of arachidonic acid (AA) to cysteinyl-leukotrienes (cys-LTs), there is now evidence that both cytokines and staphylococcus superantigens amplify the inflammatory process exacerbating the disease. cysteinyl-leukotriene 177-184 prostaglandin-endoperoxide synthase 1 Homo sapiens 67-83 22829846-3 2012 While it has been long established that NSAIDs cause inhibition of cyclooxygenase-1 (COX-1), leading to excessive metabolism of arachidonic acid (AA) to cysteinyl-leukotrienes (cys-LTs), there is now evidence that both cytokines and staphylococcus superantigens amplify the inflammatory process exacerbating the disease. cysteinyl-leukotriene 177-184 prostaglandin-endoperoxide synthase 1 Homo sapiens 85-90 21531793-0 2011 Agonist-induced desensitization/resensitization of human G protein-coupled receptor 17: a functional cross-talk between purinergic and cysteinyl-leukotriene ligands. cysteinyl-leukotriene 135-156 G protein-coupled receptor 17 Homo sapiens 57-86 21958738-3 2011 The compound concentration-dependently inhibited 5-LOX product synthesis, specifically inhibiting cysteinyl leukotriene LTC(4) with an IC(50) value of 1.80 muM, and showed no cell toxicity effects. cysteinyl-leukotriene 98-119 latexin Homo sapiens 156-159 21934409-10 2011 CONCLUSION: Cysteinyl leukotrienes importantly contribute to endotoxin-induced impairment of HPV in part via a cysteinyl leukotriene receptor 1-dependent mechanism. cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Mus musculus 111-143 21664436-1 2011 Cysteinyl leukotrienes (CysLTs), potent inflammatory mediators, are released from ischemic brain, and may regulate ischemic injury through activating CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Rattus norvegicus 150-156 21664436-1 2011 Cysteinyl leukotrienes (CysLTs), potent inflammatory mediators, are released from ischemic brain, and may regulate ischemic injury through activating CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Rattus norvegicus 161-167 21664436-1 2011 Cysteinyl leukotrienes (CysLTs), potent inflammatory mediators, are released from ischemic brain, and may regulate ischemic injury through activating CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Rattus norvegicus 150-156 21664436-1 2011 Cysteinyl leukotrienes (CysLTs), potent inflammatory mediators, are released from ischemic brain, and may regulate ischemic injury through activating CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Rattus norvegicus 161-167 21753081-0 2011 Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. cysteinyl-leukotriene 13-35 cysteinyl leukotriene receptor 2 Homo sapiens 125-131 21744154-1 2011 GPR17, a previously orphan receptor responding to both uracil nucleotides and cysteinyl-leukotrienes, has been proposed as a novel promising target for human neurodegenerative diseases. cysteinyl-leukotriene 78-100 G protein-coupled receptor 17 Homo sapiens 0-5 21531793-1 2011 G protein-coupled receptor (GPR) 17 is a P2Y-like receptor that responds to both uracil nucleotides (as UDP-glucose) and cysteinyl-leukotrienes (cysLTs, as LTD(4)). cysteinyl-leukotriene 121-143 G protein-coupled receptor 17 Homo sapiens 41-58 21148797-10 2011 These data indicate that ablation of LepRb-mediated STAT3 signaling and the associated augmentation of ERK1/2, cytosolic phospholipase A(2) alpha, and cysteinyl-leukotriene synthesis confers resistance to s/s mice during pneumococcal pneumonia. cysteinyl-leukotriene 151-172 leptin receptor Mus musculus 37-42 21321188-7 2011 Proresolving mechanisms for TLR4-defective animals included decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated CysLT1 receptor-dependent vascular permeability changes; and induction of lung suppressor of cytokine signaling 3 (SOCS3) expression that decreased TLR4-driven oxidative stress. cysteinyl-leukotriene 105-127 toll-like receptor 4 Mus musculus 28-32 21321188-7 2011 Proresolving mechanisms for TLR4-defective animals included decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated CysLT1 receptor-dependent vascular permeability changes; and induction of lung suppressor of cytokine signaling 3 (SOCS3) expression that decreased TLR4-driven oxidative stress. cysteinyl-leukotriene 105-127 cysteinyl leukotriene receptor 1 Mus musculus 162-168 21357260-12 2011 We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cell mucous secretion with LTD(4) using the CysLT(1) receptor. cysteinyl-leukotriene 17-39 cysteinyl leukotriene receptor 1 Rattus norvegicus 114-122 21357742-0 2011 Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. cysteinyl-leukotriene 57-79 C-type lectin domain family 4, member n Mus musculus 0-8 21357742-2 2011 We previously identified Dectin-2 as a receptor for glycans in allergen extracts from the house dust mite Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary CD11c+ cells and from GM-CSF-cultured bone marrow cells (BMCs(GM-CSF)). cysteinyl-leukotriene 150-171 C-type lectin domain family 4, member n Mus musculus 25-33 21357742-2 2011 We previously identified Dectin-2 as a receptor for glycans in allergen extracts from the house dust mite Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary CD11c+ cells and from GM-CSF-cultured bone marrow cells (BMCs(GM-CSF)). cysteinyl-leukotriene 150-171 integrin subunit alpha X Homo sapiens 207-212 21357742-2 2011 We previously identified Dectin-2 as a receptor for glycans in allergen extracts from the house dust mite Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary CD11c+ cells and from GM-CSF-cultured bone marrow cells (BMCs(GM-CSF)). cysteinyl-leukotriene 150-171 colony stimulating factor 2 Homo sapiens 229-235 21357742-2 2011 We previously identified Dectin-2 as a receptor for glycans in allergen extracts from the house dust mite Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary CD11c+ cells and from GM-CSF-cultured bone marrow cells (BMCs(GM-CSF)). cysteinyl-leukotriene 150-171 colony stimulating factor 2 Homo sapiens 269-275 21121979-0 2011 Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells. cysteinyl-leukotriene 0-22 vascular endothelial growth factor A Homo sapiens 30-64 20966037-1 2011 The cysteinyl-leukotrienes (cysLTs) LTC(4), LTD(4), and LTE(4), are involved in a variety of inflammatory diseases, including asthma, and act on at least two distinct receptors, CysLT(1) and CysLT(2). cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Homo sapiens 178-186 20966037-1 2011 The cysteinyl-leukotrienes (cysLTs) LTC(4), LTD(4), and LTE(4), are involved in a variety of inflammatory diseases, including asthma, and act on at least two distinct receptors, CysLT(1) and CysLT(2). cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 2 Homo sapiens 191-199 20974857-1 2010 Secreted phospholipase A(2) group X (sPLA(2)-X) has recently been identified in the airways of patients with asthma and may participate in cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synthesis. cysteinyl-leukotriene 139-160 phospholipase A2 group X Homo sapiens 0-46 21804200-6 2011 We found the expression of 5-lipoxygenase (5-LO), FLAP and the cysteinyl leukotrienes (CysLT1) mRNAs in spinal microglia, LTA4h and LTC4s mRNAs in both spinal neurons and microglia, and BLT1 mRNA in spinal neurons. cysteinyl-leukotriene 63-85 cysteinyl leukotriene receptor 1 Rattus norvegicus 87-93 21765618-2 2011 By the use of flow cytometry technique, we documented that freshly isolated mature rat peritoneal mast cells do express surface TLR2 and TLR4 protein, but not CD14 molecules, and respond to stimulation with TLR2 and TLR4 ligands by cysteinyl leukotriene generation. cysteinyl-leukotriene 232-253 toll-like receptor 2 Rattus norvegicus 128-132 21765618-2 2011 By the use of flow cytometry technique, we documented that freshly isolated mature rat peritoneal mast cells do express surface TLR2 and TLR4 protein, but not CD14 molecules, and respond to stimulation with TLR2 and TLR4 ligands by cysteinyl leukotriene generation. cysteinyl-leukotriene 232-253 toll-like receptor 2 Rattus norvegicus 207-211 21765618-2 2011 By the use of flow cytometry technique, we documented that freshly isolated mature rat peritoneal mast cells do express surface TLR2 and TLR4 protein, but not CD14 molecules, and respond to stimulation with TLR2 and TLR4 ligands by cysteinyl leukotriene generation. cysteinyl-leukotriene 232-253 toll-like receptor 4 Rattus norvegicus 216-220 20980252-1 2010 Human leukotriene C(4) synthase (hLTC(4)S) is an integral membrane enzyme that conjugates leukotriene (LT) A(4) with glutathione to form LTC(4), a precursor to the cysteinyl leukotrienes (LTC(4), LTD(4), and LTE(4)) that are involved in the pathogenesis of human bronchial asthma. cysteinyl-leukotriene 164-186 leukotriene C4 synthase Homo sapiens 6-31 20980252-1 2010 Human leukotriene C(4) synthase (hLTC(4)S) is an integral membrane enzyme that conjugates leukotriene (LT) A(4) with glutathione to form LTC(4), a precursor to the cysteinyl leukotrienes (LTC(4), LTD(4), and LTE(4)) that are involved in the pathogenesis of human bronchial asthma. cysteinyl-leukotriene 164-186 leukotriene C4 synthase Homo sapiens 33-41 20974857-1 2010 Secreted phospholipase A(2) group X (sPLA(2)-X) has recently been identified in the airways of patients with asthma and may participate in cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synthesis. cysteinyl-leukotriene 139-160 ubiquitination factor E4A Homo sapiens 185-189 20056144-1 2010 The P2Y-like receptor GPR17 has been reported to respond to both uracil nucleotides and cysteinyl-leukotrienes (cysLTs), such as UDP-glucose and LTD(4). cysteinyl-leukotriene 88-110 G protein-coupled receptor 17 Rattus norvegicus 22-27 20944008-4 2010 PTPalpha(-/-) bone marrow-derived mast cells hyperdegranulate and exhibit increased cytokine and cysteinyl leukotriene secretion, and PTPalpha(-/-) mice display enhanced IgE-dependent anaphylaxis. cysteinyl-leukotriene 97-118 protein phosphatase 2 protein activator Mus musculus 0-8 20602614-1 2010 AIMS: Cysteinyl leukotrienes are inactivated by acetyl coenzyme A-dependent N-acetyltransferase (NAT). cysteinyl-leukotriene 6-28 bromodomain containing 2 Homo sapiens 97-100 20394377-2 2010 GPR17 is dually activated by uracil nucleotides and cysteinyl-leukotrienes, and is expressed in organs typically undergoing ischemic damage (i.e., brain, heart and kidney), thus representing a new pharmacological target for acute and chronic neurodegeneration. cysteinyl-leukotriene 52-74 G protein-coupled receptor 17 Homo sapiens 0-5 21078989-3 2010 Here we report that mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), and LTC(4) synthase (LTC(4)S), are significantly increased in the wall of human abdominal aortic aneurysms (AAAs). cysteinyl-leukotriene 90-112 leukotriene C4 synthase Homo sapiens 173-188 21078989-3 2010 Here we report that mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), and LTC(4) synthase (LTC(4)S), are significantly increased in the wall of human abdominal aortic aneurysms (AAAs). cysteinyl-leukotriene 90-112 leukotriene C4 synthase Homo sapiens 190-197 21105577-1 2010 Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that induce inflammation through the activation of CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Rattus norvegicus 117-123 21105577-1 2010 Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that induce inflammation through the activation of CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Rattus norvegicus 128-134 21105577-1 2010 Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that induce inflammation through the activation of CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Rattus norvegicus 117-123 21105577-1 2010 Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that induce inflammation through the activation of CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Rattus norvegicus 128-134 20805171-7 2010 Regression analysis showed a significant association between log OPN and sputum eosinophils, cysteinyl leukotrienes, IL-13, TGF-beta1 and ECP. cysteinyl-leukotriene 93-115 secreted phosphoprotein 1 Homo sapiens 65-68 20805171-11 2010 Moreover, OPN is associated with mediators involved in both the inflammatory and remodelling process such as TGF-beta1, IL-13 and cysteinyl leukotrienes only in SRA. cysteinyl-leukotriene 130-152 secreted phosphoprotein 1 Homo sapiens 10-13 20462748-1 2010 Cysteinyl leukotrienes (CysLTs) contribute to allergic and inflammatory diseases through CysLT(1)-R. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 89-99 20432503-5 2010 Mechanistically, group V sPLA2 counter-regulation includes promotion of immune complex clearance by regulating cysteinyl leukotriene synthesis. cysteinyl-leukotriene 111-132 phospholipase A2, group IIA (platelets, synovial fluid) Mus musculus 25-30 20433311-5 2010 Moreover, we examined the effect of cysteinyl leukotrienes (CysLTs) in platelets on the induction of RANTES (Regulated on Activation, Normal T Expressed, and presumably Secreted). cysteinyl-leukotriene 36-58 C-C motif chemokine ligand 5 Homo sapiens 101-107 20064706-2 2010 In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. cysteinyl-leukotriene 78-100 cysteinyl leukotriene receptor 1 Homo sapiens 201-210 20064706-2 2010 In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. cysteinyl-leukotriene 78-100 cysteinyl leukotriene receptor 2 Homo sapiens 245-254 20139896-3 2010 RESULTS: Both baicalin and zileuton attenuated OGD/recovery- and H(2)O(2)-induced injury and inhibited OGD/recovery-induced production of 5-LOX metabolites (cysteinyl leukotrienes) in a concentration-dependent manner. cysteinyl-leukotriene 157-179 arachidonate 5-lipoxygenase Rattus norvegicus 138-143 20233425-1 2010 BACKGROUND: GPR17 is a hybrid G-protein-coupled receptor (GPCR) activated by two unrelated ligand families, extracellular nucleotides and cysteinyl-leukotrienes (cysteinyl-LTs), and involved in brain damage and repair. cysteinyl-leukotriene 138-160 G protein-coupled receptor 17 Homo sapiens 12-17 19647860-1 2009 The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4), is formed by conjugation of LTA(4) and reduced glutathione by LTC(4) synthase in mast cells, eosinophils, basophils, and macrophages. cysteinyl-leukotriene 32-54 leukotriene C4 synthase Rattus norvegicus 150-165 19876784-3 2009 By blocking the formation of both leukotriene B4 and the cysteinyl leukotrienes (ie, LTC4 , LTD4 and LTE4), FLAP inhibitors act as broad-spectrum leukotriene-modifier drugs that may have a wide range of therapeutic applications. cysteinyl-leukotriene 57-79 arachidonate 5-lipoxygenase activating protein Homo sapiens 108-112 19625605-1 2009 The previously "orphan" G protein-coupled receptor GPR17 is structurally related to both P2Y nucleotide receptors and to receptors for cysteinyl leukotrienes. cysteinyl-leukotriene 135-157 G protein-coupled receptor 17 Homo sapiens 51-56 19625605-6 2009 [35S]GTPgammaS binding in long-GPR17-expressing 1321N1 cells revealed concentration-dependent responses to uracil nucleotides (UDP-galactose = UDP > UDP-glucose) and cysteinyl leukotrienes (LTC4 > LTD4), which were counteracted by a purinergic (cangrelor) and a cysteinyl leukotriene antagonist (montelukast), respectively. cysteinyl-leukotriene 169-191 G protein-coupled receptor 17 Homo sapiens 31-36 19625605-6 2009 [35S]GTPgammaS binding in long-GPR17-expressing 1321N1 cells revealed concentration-dependent responses to uracil nucleotides (UDP-galactose = UDP > UDP-glucose) and cysteinyl leukotrienes (LTC4 > LTD4), which were counteracted by a purinergic (cangrelor) and a cysteinyl leukotriene antagonist (montelukast), respectively. cysteinyl-leukotriene 169-190 G protein-coupled receptor 17 Homo sapiens 31-36 19625605-10 2009 We conclude that the previously uncharacterized long-GPR17 isoform is a functional receptor that is stimulated by both uracil nucleotides and cysteinyl leukotrienes. cysteinyl-leukotriene 142-164 G protein-coupled receptor 17 Homo sapiens 53-58 19767084-12 2009 Assuming that normal monocytes behave like monocytes from patients with aspirin-exacerbated respiratory disease, inhibition of IL-4-STAT6 might explain a mechanism in aspirin desensitization daily treatment, resulting in downregulation of production and responsiveness to cysteinyl leukotrienes. cysteinyl-leukotriene 272-294 interleukin 4 Homo sapiens 127-137 19647860-1 2009 The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4), is formed by conjugation of LTA(4) and reduced glutathione by LTC(4) synthase in mast cells, eosinophils, basophils, and macrophages. cysteinyl-leukotriene 56-62 leukotriene C4 synthase Rattus norvegicus 150-165 19759251-5 2009 Cysteinyl leukotrienes (CysLTs) are known promoters of allergy and inflammation, and the first step in their biogenesis from arachidonic acid is catalyzed by 5-lipoxygenase (5-LO) in concert with the 5-LO-activating protein (FLAP). cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 158-172 19759251-5 2009 Cysteinyl leukotrienes (CysLTs) are known promoters of allergy and inflammation, and the first step in their biogenesis from arachidonic acid is catalyzed by 5-lipoxygenase (5-LO) in concert with the 5-LO-activating protein (FLAP). cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase Homo sapiens 158-172 19454674-3 2009 Particularly CysLT(1), a G protein-coupled receptor recognizing inflammatory mediators of the cysteinyl leukotriene family, is highly expressed in HPCs. cysteinyl-leukotriene 94-115 cysteinyl leukotriene receptor 1 Homo sapiens 13-21 19561298-1 2009 The cysteinyl leukotrienes (cys-LTs) are proinflammatory lipid mediators acting on the type 1 cys-LT receptor (CysLT(1)R) to mediate smooth muscle constriction and vascular permeability. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Mus musculus 111-120 19561298-1 2009 The cysteinyl leukotrienes (cys-LTs) are proinflammatory lipid mediators acting on the type 1 cys-LT receptor (CysLT(1)R) to mediate smooth muscle constriction and vascular permeability. cysteinyl-leukotriene 28-35 cysteinyl leukotriene receptor 1 Mus musculus 111-120 19347252-1 2009 OBJECTIVE AND DESIGN: In the present study, we investigated the relation between the inflammatory mediators such as nitric oxide, prostaglandins, and cysteinyl-leukotrienes with mucin release and the sympathetic system in submandibular glands from rats with experimental periodontitis. cysteinyl-leukotriene 150-172 solute carrier family 13 member 2 Rattus norvegicus 178-183 19347252-10 2009 Either the inhibition of cysteinyl-leukotriene production or the block of leukotriene receptor abolished the increase in mucin secretion by 25.6% (P < 0.05) and 37% (P < 0.01), respectively, in glands from rats with ligature. cysteinyl-leukotriene 25-46 solute carrier family 13 member 2 Rattus norvegicus 121-126 19347252-11 2009 On the other hand, the presence of cysteinyl-leukotrienes in the incubation medium induced mucin release from submandibular glands. cysteinyl-leukotriene 35-57 solute carrier family 13 member 2 Rattus norvegicus 91-96 19528093-2 2009 Here we show that, in non-injured spinal cord parenchyma, GPR17, a P2Y-like receptor responding to both uracil nucleotides (e.g. UDP-glucose) and cysteinyl-leukotrienes (e.g. LTD4 and LTC4), is present on a subset of neurons and of oligodendrocytes at different stages of maturation, whereas it is not expressed by astrocytes. cysteinyl-leukotriene 146-168 G protein-coupled receptor 17 Homo sapiens 58-63 19528093-2 2009 Here we show that, in non-injured spinal cord parenchyma, GPR17, a P2Y-like receptor responding to both uracil nucleotides (e.g. UDP-glucose) and cysteinyl-leukotrienes (e.g. LTD4 and LTC4), is present on a subset of neurons and of oligodendrocytes at different stages of maturation, whereas it is not expressed by astrocytes. cysteinyl-leukotriene 146-168 G protein-coupled receptor 17 Homo sapiens 67-84 19528093-11 2009 Thus, GPR17 may act as a "sensor" of damage that is activated by nucleotides and cysteinyl-leukotrienes released in the lesioned area, and could also participate in post-injury responses. cysteinyl-leukotriene 81-103 G protein-coupled receptor 17 Homo sapiens 6-11 19398503-8 2009 Finally, the differing abilities of the cysteinyl leukotriene derivatives leukotriene C(4), D(4), and F(4) to inhibit estradiol glucuronide transport by wild-type and K332L mutant MRP1 provide further evidence that TM6-Lys(332) is involved in the recognition of the gamma-Glu portion of substrates and modulators containing GSH or GSH-like moieties. cysteinyl-leukotriene 40-61 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 19416143-3 2009 Cysteinyl leukotrienes (LTC(4), LTD(4) and, LTE(4)) and the dihydroxy leukotriene LTB(4) are generated by a series of enzymes/proteins constituting the LT synthetic pathway or 5-lipoxygenase (5-LO) pathway. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 176-190 19299719-7 2009 We recorded that M. sympodialis induced release of cysteinyl leukotrienes in a dose-dependent manner in nonsensitized and IgE-anti-trinitrophenyl-sensitized BMMCs, respectively, with three times higher levels in the latter type of cells. cysteinyl-leukotriene 51-73 immunoglobulin heavy constant epsilon Homo sapiens 122-125 19234368-1 2009 The actions of cysteinyl leukotrienes (CysLTs) are mediated by activating CysLT receptors, CysLT(1), and CysLT(2). cysteinyl-leukotriene 15-37 cysteinyl leukotriene receptor 1 Homo sapiens 91-98 18978154-7 2009 The paracrine signal was identified as a cysteinyl leukotriene because 1) RNAi knockdown or pharmacological block of the 5-lipoxygenase enzyme prevented activated mast cells from stimulating resting cells. cysteinyl-leukotriene 41-62 arachidonate 5-lipoxygenase Rattus norvegicus 121-135 19234368-1 2009 The actions of cysteinyl leukotrienes (CysLTs) are mediated by activating CysLT receptors, CysLT(1), and CysLT(2). cysteinyl-leukotriene 15-37 cysteinyl leukotriene receptor 2 Homo sapiens 105-112 19124755-0 2009 Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. cysteinyl-leukotriene 49-70 C-type lectin domain family 4, member n Mus musculus 0-8 19124755-7 2009 Lung CD11c+ cells, but not peritoneal or alveolar macrophages, also generated cys-LTs in response to Df. cysteinyl-leukotriene 78-85 integrin subunit alpha X Homo sapiens 5-10 19124756-0 2009 P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells. cysteinyl-leukotriene 33-54 pyrimidinergic receptor P2Y6 Homo sapiens 0-4 19124756-1 2009 Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 79-86 19124756-1 2009 Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 100-107 19124756-1 2009 Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 1 Homo sapiens 79-86 19124756-1 2009 Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 2 Homo sapiens 100-107 19218821-0 2009 Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. cysteinyl-leukotriene 0-22 C-C motif chemokine ligand 2 Homo sapiens 30-64 18931056-1 2009 Multidrug resistance-associated protein 1 (MRP1) is a cysteinyl leukotriene (CysLT) export pump expressed on mast cells. cysteinyl-leukotriene 54-75 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 0-41 18931056-1 2009 Multidrug resistance-associated protein 1 (MRP1) is a cysteinyl leukotriene (CysLT) export pump expressed on mast cells. cysteinyl-leukotriene 54-75 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 43-47 19218821-1 2009 BACKGROUND: We have previously demonstrated that cysteinyl leukotriene (CysLT) induced monocyte chemoattractant protein-1 (MCP-1) production in monocytes/macrophages. cysteinyl-leukotriene 49-70 C-C motif chemokine ligand 2 Homo sapiens 87-121 19218821-1 2009 BACKGROUND: We have previously demonstrated that cysteinyl leukotriene (CysLT) induced monocyte chemoattractant protein-1 (MCP-1) production in monocytes/macrophages. cysteinyl-leukotriene 49-70 C-C motif chemokine ligand 2 Homo sapiens 123-128 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Mus musculus 109-123 18797182-4 2008 The LTB(4)/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. cysteinyl-leukotriene 226-248 leukotriene B4 receptor 1 Mus musculus 11-15 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase activating protein Mus musculus 157-161 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 0-22 leukotriene C4 synthase Mus musculus 164-189 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase Mus musculus 109-123 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 24-30 arachidonate 5-lipoxygenase activating protein Mus musculus 157-161 18779380-1 2008 Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C(4) synthase, and additional downstream enzymes, starting with arachidonic acid substrate. cysteinyl-leukotriene 24-30 leukotriene C4 synthase Mus musculus 164-189 19180262-5 2008 Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 53-67 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 121-135 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 268-274 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 279-285 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 0-22 leukotriene B4 receptor Homo sapiens 307-311 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 0-22 leukotriene B4 receptor 2 Homo sapiens 316-320 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 24-31 arachidonate 5-lipoxygenase Homo sapiens 121-135 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 1 Homo sapiens 268-274 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 2 Homo sapiens 279-285 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 24-31 leukotriene B4 receptor Homo sapiens 307-311 18794213-1 2008 Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). cysteinyl-leukotriene 24-31 leukotriene B4 receptor 2 Homo sapiens 316-320 18456799-9 2008 In addition, GM-CSF-/- BMT AMs retained cysteinyl leukotriene production and normal TNF-alpha response compared with AMs from control BMT mice. cysteinyl-leukotriene 40-61 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 13-19 18653647-10 2008 Allergen-induced airway epithelial and airway smooth muscle remodelling is mediated by cysteinyl leukotrienes via the cysteinyl leukotriene-1 receptor with downstream effects on the epidermal growth factor receptor axis. cysteinyl-leukotriene 87-109 epidermal growth factor receptor Rattus norvegicus 182-214 18490762-0 2008 IL-10 inhibits cysteinyl leukotriene-induced activation of human monocytes and monocyte-derived dendritic cells. cysteinyl-leukotriene 15-36 interleukin 10 Homo sapiens 0-5 20525128-7 2008 Leukotriene C4 (LTC4) synthase is the enzyme responsible for the production of leukotriene C4, the chief cysteinyl leukotriene responsible for AEA. cysteinyl-leukotriene 105-126 leukotriene C4 synthase Homo sapiens 0-30 18286646-2 2008 Cysteinyl leukotrienes are proinflammatory 5-lipoxygenase-derived products that play a major role in the immune and inflammatory response. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 43-57 18503712-0 2008 Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. cysteinyl-leukotriene 97-119 tenascin C Homo sapiens 13-21 18537720-1 2008 Leukotrienes (LTs), including LTB(4) and cysteinyl-LTs (CysLTs) (LTC(4), LTD(4), and LTE(4)), are potent inflammatory lipid mediators which are derived from 5-lipoxygenase activity. cysteinyl-leukotriene 41-54 arachidonate 5-lipoxygenase Homo sapiens 157-171 18503712-0 2008 Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. cysteinyl-leukotriene 97-119 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-39 18503712-0 2008 Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. cysteinyl-leukotriene 97-119 cysteinyl leukotriene receptor 1 Homo sapiens 124-130 18186807-0 2008 Role of cysteinyl leukotrienes in human allergen-specific Th2 responses induced by granulocyte macrophage-colony stimulating factor. cysteinyl-leukotriene 8-30 colony stimulating factor 2 Homo sapiens 83-131 18204779-1 2008 Cysteinyl-leukotrienes are important pro-inflammatory mediators in bronchial asthma (BA) and are derived from arachidonic acid by the action of 5-lipoxygenase. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 144-158 17910051-1 2008 We recently found that 5-lipoxygenase (5-LOX) is activated to produce cysteinyl leukotrienes (CysLTs), and CysLTs may cause neuronal injury and astrocytosis through activation of CysLT(1) and CysLT(2) receptors in the brain after focal cerebral ischemia. cysteinyl-leukotriene 70-92 arachidonate 5-lipoxygenase Rattus norvegicus 23-37 18048362-2 2008 Cysteinyl-leukotrienes are involved in inflammation and act on at least two G-protein-coupled receptors, CysLT1 and CysLT2. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 105-111 18048362-2 2008 Cysteinyl-leukotrienes are involved in inflammation and act on at least two G-protein-coupled receptors, CysLT1 and CysLT2. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 116-122 17910051-1 2008 We recently found that 5-lipoxygenase (5-LOX) is activated to produce cysteinyl leukotrienes (CysLTs), and CysLTs may cause neuronal injury and astrocytosis through activation of CysLT(1) and CysLT(2) receptors in the brain after focal cerebral ischemia. cysteinyl-leukotriene 70-92 arachidonate 5-lipoxygenase Rattus norvegicus 39-44 17910051-1 2008 We recently found that 5-lipoxygenase (5-LOX) is activated to produce cysteinyl leukotrienes (CysLTs), and CysLTs may cause neuronal injury and astrocytosis through activation of CysLT(1) and CysLT(2) receptors in the brain after focal cerebral ischemia. cysteinyl-leukotriene 70-92 cysteinyl leukotriene receptor 1 Rattus norvegicus 179-187 17611132-4 2008 To study the role of cysteinyl leukotrienes in neurokinin A-induced bronchoconstriction, we performed a randomised, double-blind, cross-over, placebo controlled trial in 12 patients with mild to moderate asthma. cysteinyl-leukotriene 21-43 tachykinin precursor 1 Homo sapiens 47-59 19009039-0 2008 PPARalpha/gamma-Independent Effects of PPARalpha/gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells. cysteinyl-leukotriene 66-87 peroxisome proliferator activated receptor alpha Mus musculus 0-9 19009039-0 2008 PPARalpha/gamma-Independent Effects of PPARalpha/gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells. cysteinyl-leukotriene 66-87 peroxisome proliferator activated receptor alpha Mus musculus 39-48 19009039-1 2008 Peroxisome proliferator-activated receptor (PPAR) alpha ligands (Wy-14,643, and fenofibrate) and PPARgamma ligands (troglitazone and ciglitazone) inhibit antigen-induced cysteinyl leukotriene production in immunoglobulin E-treated mast cells. cysteinyl-leukotriene 170-191 peroxisome proliferator activated receptor alpha Mus musculus 0-42 19009039-1 2008 Peroxisome proliferator-activated receptor (PPAR) alpha ligands (Wy-14,643, and fenofibrate) and PPARgamma ligands (troglitazone and ciglitazone) inhibit antigen-induced cysteinyl leukotriene production in immunoglobulin E-treated mast cells. cysteinyl-leukotriene 170-191 peroxisome proliferator activated receptor alpha Mus musculus 44-48 19009039-1 2008 Peroxisome proliferator-activated receptor (PPAR) alpha ligands (Wy-14,643, and fenofibrate) and PPARgamma ligands (troglitazone and ciglitazone) inhibit antigen-induced cysteinyl leukotriene production in immunoglobulin E-treated mast cells. cysteinyl-leukotriene 170-191 peroxisome proliferator activated receptor gamma Mus musculus 97-106 19009039-5 2008 The mechanisms of the PPAR-independent inhibition by these agents on cysteinyl leukotriene production are discussed in this review. cysteinyl-leukotriene 69-90 peroxisome proliferator activated receptor alpha Mus musculus 22-26 17239638-1 2008 OBJECTIVES: Histamine and cysteinyl leukotrienes play an important role in early (EAR) and late (LAR) allergen reactions. cysteinyl-leukotriene 26-48 protein tyrosine phosphatase receptor type F Homo sapiens 97-100 17904626-0 2007 Blockade of avidity and focal clustering of beta 2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion. cysteinyl-leukotriene 63-84 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 44-50 17901411-1 2007 RATIONALE: Secreted phospholipase A(2) enzymes (sPLA(2)s) play key regulatory roles in the biosynthesis of eicosanoids, such as the cysteinyl leukotrienes, but the role of these enzymes in the pathogenesis of asthma is not known. cysteinyl-leukotriene 132-154 phospholipase A2 group IID Homo sapiens 11-46 17901411-1 2007 RATIONALE: Secreted phospholipase A(2) enzymes (sPLA(2)s) play key regulatory roles in the biosynthesis of eicosanoids, such as the cysteinyl leukotrienes, but the role of these enzymes in the pathogenesis of asthma is not known. cysteinyl-leukotriene 132-154 phospholipase A2 group IID Homo sapiens 48-56 17693579-0 2007 CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. cysteinyl-leukotriene 66-87 cysteinyl leukotriene receptor 2 Homo sapiens 0-6 17693579-1 2007 Cysteinyl leukotrienes (cys-LTs) induce inflammation through 2 G protein-coupled receptors (GPCRs), CysLT(1) and CysLT(2), which are coexpressed by most myeloid cells. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 100-108 17693579-1 2007 Cysteinyl leukotrienes (cys-LTs) induce inflammation through 2 G protein-coupled receptors (GPCRs), CysLT(1) and CysLT(2), which are coexpressed by most myeloid cells. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 113-120 17693579-1 2007 Cysteinyl leukotrienes (cys-LTs) induce inflammation through 2 G protein-coupled receptors (GPCRs), CysLT(1) and CysLT(2), which are coexpressed by most myeloid cells. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 1 Homo sapiens 100-108 17693579-1 2007 Cysteinyl leukotrienes (cys-LTs) induce inflammation through 2 G protein-coupled receptors (GPCRs), CysLT(1) and CysLT(2), which are coexpressed by most myeloid cells. cysteinyl-leukotriene 24-31 cysteinyl leukotriene receptor 2 Homo sapiens 113-120 17693579-2 2007 Cys-LTs induce proliferation of mast cells (MCs), transactivate c-Kit, and phosphorylate extracellular signal-regulated kinase (ERK). cysteinyl-leukotriene 0-7 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 44-47 17693579-2 2007 Cys-LTs induce proliferation of mast cells (MCs), transactivate c-Kit, and phosphorylate extracellular signal-regulated kinase (ERK). cysteinyl-leukotriene 0-7 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 64-69 17693579-2 2007 Cys-LTs induce proliferation of mast cells (MCs), transactivate c-Kit, and phosphorylate extracellular signal-regulated kinase (ERK). cysteinyl-leukotriene 0-7 mitogen-activated protein kinase 1 Homo sapiens 89-126 17693579-2 2007 Cys-LTs induce proliferation of mast cells (MCs), transactivate c-Kit, and phosphorylate extracellular signal-regulated kinase (ERK). cysteinyl-leukotriene 0-7 mitogen-activated protein kinase 1 Homo sapiens 128-131 17991613-1 2007 The 5-lipoxygenase (5-LO) pathway generates lipid mediators, i.e. the cysteinyl leukotrienes (cysLTs) LTC(4)/LTD(4) and LTB(4). cysteinyl-leukotriene 70-92 arachidonate 5-lipoxygenase Homo sapiens 4-18 17627772-1 2007 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through the receptors, cysLT1R and cysLTR2, and are produced by eosinophils derived from eosinophil/basophil (Eo/B) bone marrow (BM) progenitors. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Mus musculus 114-121 17627772-1 2007 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through the receptors, cysLT1R and cysLTR2, and are produced by eosinophils derived from eosinophil/basophil (Eo/B) bone marrow (BM) progenitors. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 2 Mus musculus 126-133 17627772-1 2007 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through the receptors, cysLT1R and cysLTR2, and are produced by eosinophils derived from eosinophil/basophil (Eo/B) bone marrow (BM) progenitors. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 1 Mus musculus 114-121 17627772-1 2007 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through the receptors, cysLT1R and cysLTR2, and are produced by eosinophils derived from eosinophil/basophil (Eo/B) bone marrow (BM) progenitors. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 2 Mus musculus 126-133 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 1 Homo sapiens 196-211 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 1 Homo sapiens 213-220 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 2 Homo sapiens 226-241 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 2 Homo sapiens 243-250 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 40-46 cysteinyl leukotriene receptor 1 Homo sapiens 196-211 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 40-46 cysteinyl leukotriene receptor 1 Homo sapiens 213-220 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 40-46 cysteinyl leukotriene receptor 2 Homo sapiens 226-241 17941281-1 2007 BACKGROUND: The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). cysteinyl-leukotriene 40-46 cysteinyl leukotriene receptor 2 Homo sapiens 243-250 17632546-3 2007 This intermediate is conjugated with glutathione (GSH) to produce leukotriene C4 (LTC4) in a reaction catalysed by LTC4 synthase: this reaction is the key step in cysteinyl leukotriene formation. cysteinyl-leukotriene 163-184 leukotriene C4 synthase Homo sapiens 115-128 17496151-7 2007 Whereas the fibrotic effects of bleomycin were not altered in wild-type or COX-2 knockout mice overexpressing COX-1, the exaggerated lung function decrement in bleomycin-treated COX-2 knockout mice was prevented by COX-1 overexpression and coincided with decreased airway cysteinyl leukotriene levels. cysteinyl-leukotriene 272-293 cytochrome c oxidase II, mitochondrial Mus musculus 178-183 17496151-7 2007 Whereas the fibrotic effects of bleomycin were not altered in wild-type or COX-2 knockout mice overexpressing COX-1, the exaggerated lung function decrement in bleomycin-treated COX-2 knockout mice was prevented by COX-1 overexpression and coincided with decreased airway cysteinyl leukotriene levels. cysteinyl-leukotriene 272-293 cytochrome c oxidase I, mitochondrial Mus musculus 215-220 17632548-11 2007 These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple cysteinyl leukotriene receptors whose functions may be non-redundant. cysteinyl-leukotriene 130-151 leukotriene C4 synthase Homo sapiens 65-70 18516250-2 2007 The present study describes a practical preparation of cysteinyl leukotrienes (leukotriene C(4), D(4) and E(4)) with three (13)C atoms and one (15)N atom in the cysteinyl residue. cysteinyl-leukotriene 55-77 Rho GDP dissociation inhibitor beta Homo sapiens 79-110 17360805-7 2007 By analysis of downstream signaling, we could provide further evidence that combined activation of PTX-insensitive (Gq-mediated) and PTX-sensitive (Gi-mediated) pathways by cysLT1 may explain the strong and broad effects of cysteinyl-leukotrienes in early hematopoietic cells, while signaling of CXCR4 and S1P1 solely depends on Gi proteins, resulting in effects mainly restricted to migration and adhesion. cysteinyl-leukotriene 224-246 cysteinyl leukotriene receptor 1 Homo sapiens 173-179 17360805-7 2007 By analysis of downstream signaling, we could provide further evidence that combined activation of PTX-insensitive (Gq-mediated) and PTX-sensitive (Gi-mediated) pathways by cysLT1 may explain the strong and broad effects of cysteinyl-leukotrienes in early hematopoietic cells, while signaling of CXCR4 and S1P1 solely depends on Gi proteins, resulting in effects mainly restricted to migration and adhesion. cysteinyl-leukotriene 224-246 C-X-C motif chemokine receptor 4 Homo sapiens 296-301 17360805-7 2007 By analysis of downstream signaling, we could provide further evidence that combined activation of PTX-insensitive (Gq-mediated) and PTX-sensitive (Gi-mediated) pathways by cysLT1 may explain the strong and broad effects of cysteinyl-leukotrienes in early hematopoietic cells, while signaling of CXCR4 and S1P1 solely depends on Gi proteins, resulting in effects mainly restricted to migration and adhesion. cysteinyl-leukotriene 224-246 sphingosine-1-phosphate receptor 1 Homo sapiens 306-310 17397868-1 2007 BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is an important clinical issue and relates to cysteinyl leukotrienes (LTs), the first committed synthesis step of which is that LTC4 synthesis enzymes including leukotriene C4 synthase (LTC4S), microsomal glutathione-S-transferase (mGST)2, and mGST3-catalyzed LTA4 and reduced glutathione (GSH), to generate LTC4. cysteinyl-leukotriene 100-122 leukotriene C4 synthase Rattus norvegicus 215-238 17397868-1 2007 BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is an important clinical issue and relates to cysteinyl leukotrienes (LTs), the first committed synthesis step of which is that LTC4 synthesis enzymes including leukotriene C4 synthase (LTC4S), microsomal glutathione-S-transferase (mGST)2, and mGST3-catalyzed LTA4 and reduced glutathione (GSH), to generate LTC4. cysteinyl-leukotriene 100-122 leukotriene C4 synthase Rattus norvegicus 240-245 17397868-1 2007 BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is an important clinical issue and relates to cysteinyl leukotrienes (LTs), the first committed synthesis step of which is that LTC4 synthesis enzymes including leukotriene C4 synthase (LTC4S), microsomal glutathione-S-transferase (mGST)2, and mGST3-catalyzed LTA4 and reduced glutathione (GSH), to generate LTC4. cysteinyl-leukotriene 100-122 microsomal glutathione S-transferase 2 Mus musculus 286-292 17397868-1 2007 BACKGROUND: Hepatic ischemia-reperfusion (I/R) injury is an important clinical issue and relates to cysteinyl leukotrienes (LTs), the first committed synthesis step of which is that LTC4 synthesis enzymes including leukotriene C4 synthase (LTC4S), microsomal glutathione-S-transferase (mGST)2, and mGST3-catalyzed LTA4 and reduced glutathione (GSH), to generate LTC4. cysteinyl-leukotriene 100-122 glutathione S-transferase, pi 2 Mus musculus 298-303 17404310-0 2007 IFN-gamma induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. cysteinyl-leukotriene 124-146 interferon gamma Homo sapiens 0-9 17437683-8 2007 The second class is an inhibitor of the 5-lipoxygenase enzyme that prevents synthesis of both the cysteinyl leukotrienes and leukotriene B(4). cysteinyl-leukotriene 98-120 arachidonate 5-lipoxygenase Homo sapiens 40-54 17460547-10 2007 CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy. cysteinyl-leukotriene 86-107 cysteinyl leukotriene receptor 2 Homo sapiens 0-7 17394438-1 2007 The 5-Lipoxygenase pathway results in the formation of leukotrienes, including leukotriene B(4) (LTB(4)), 5-oxo-6E,8Z,11Z,14Z-eicosatetranoic acid and the cysteinyl leukotrienes (LTC(4), LTD(4) and LTE(4)) and activates all four leukotriene receptors, BLT1, BLT2, cysLT(1) and cysLT(2). cysteinyl-leukotriene 155-177 arachidonate 5-lipoxygenase Homo sapiens 4-18 17430359-0 2007 Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. cysteinyl-leukotriene 0-22 matrix metallopeptidase 9 Homo sapiens 68-94 17460547-2 2007 Genetic variability in 5-lipoxygenase biosynthetic and receptor pathway gene loci may influence cysteinyl-leukotriene production and subsequent response to leukotriene modifiers. cysteinyl-leukotriene 96-117 arachidonate 5-lipoxygenase Homo sapiens 23-37 17460547-10 2007 CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy. cysteinyl-leukotriene 86-107 arachidonate 5-lipoxygenase Homo sapiens 12-17 17187986-6 2007 During 0.5- to 2-h recovery after 1.5-h OGD, the production of 5-LOX metabolites, cysteinyl leukotrienes, was increased; this increased production was inhibited by baicalin and MK-801, while both the increased and baseline production were inhibited by caffeic acid. cysteinyl-leukotriene 82-104 arachidonate 5-lipoxygenase Rattus norvegicus 63-68 17113579-0 2007 Peroxisome proliferator-activated receptor alpha-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells. cysteinyl-leukotriene 100-121 peroxisome proliferator activated receptor alpha Mus musculus 0-48 17113579-9 2007 Wy-14,643 (30 microM) and fenofibrate (100 microM) inhibited the cysteinyl leukotriene production in bone marrow-derived mast cells from PPARalpha-null mice. cysteinyl-leukotriene 65-86 peroxisome proliferator activated receptor alpha Mus musculus 137-146 17110605-6 2007 CONCLUSIONS: LTC4S plays a key role in the process of inflammation as the rate limiting enzyme in the conversion of arachidonic acid to cysteinyl-leukotrienes, important mediators of inflammatory responses. cysteinyl-leukotriene 136-158 leukotriene C4 synthase Homo sapiens 13-18 17182589-6 2007 When PD1 was administered before aeroallergen challenge, airway eosinophil and T lymphocyte recruitment were decreased, as were airway mucus, levels of specific proinflammatory mediators, including IL-13, cysteinyl leukotrienes, and PGD(2), and airway hyperresponsiveness to inhaled methacholine. cysteinyl-leukotriene 205-227 ribosomal protein L17 Homo sapiens 5-8 17196746-1 2007 Cysteinyl leukotrienes (CysLTs) induce inflammatory responses mediated by activating CysLT(1) and CysLT(2) receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Rattus norvegicus 85-93 17196746-1 2007 Cysteinyl leukotrienes (CysLTs) induce inflammatory responses mediated by activating CysLT(1) and CysLT(2) receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Rattus norvegicus 85-93 16980379-1 2007 We studied the effect of tumor necrosis factor (TNF)-alpha exposure on cysteinyl leukotriene (LT) synthesis by cells of monocyte/macrophage lineage. cysteinyl-leukotriene 71-92 tumor necrosis factor Homo sapiens 25-58 16990797-1 2006 Nucleotides and cysteinyl-leukotrienes (CysLTs) are unrelated signaling molecules inducing multiple effects through separate G-protein-coupled receptors: the P2Y and the CysLT receptors. cysteinyl-leukotriene 16-38 purinergic receptor P2Y1 Rattus norvegicus 158-161 17208594-1 2007 BACKGROUND: Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein-coupled receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R). cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Homo sapiens 162-169 17208594-1 2007 BACKGROUND: Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein-coupled receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R). cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 2 Homo sapiens 199-206 17208594-1 2007 BACKGROUND: Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein-coupled receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R). cysteinyl-leukotriene 36-43 cysteinyl leukotriene receptor 1 Homo sapiens 162-169 17208594-1 2007 BACKGROUND: Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein-coupled receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R). cysteinyl-leukotriene 36-43 cysteinyl leukotriene receptor 2 Homo sapiens 199-206 17208595-0 2007 Cysteinyl leukotriene upregulates IL-11 expression in allergic airway disease of mice. cysteinyl-leukotriene 0-21 interleukin 11 Mus musculus 34-39 17063752-2 2006 Leukotriene C4 synthase (LTC4S) is the critical terminal pathway enzyme involved in regulation of cysteinyl leukotriene (CysLT) synthesis. cysteinyl-leukotriene 98-119 leukotriene C4 synthase Homo sapiens 0-23 17450683-5 2006 Cysteinyl leukotrienes are vasoconstrictors and induce endothelium-dependent vascular responses through the CysLT, and CysLT2 receptor subtypes. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 119-125 17030235-12 2006 CONCLUSION: These data demonstrate mast cell expression of the coreceptor dectin-1 and a role for this molecule in the generation of cysteinyl leukotrienes. cysteinyl-leukotriene 133-155 C-type lectin domain containing 7A Homo sapiens 74-82 16824548-5 2006 As 5-LOX metabolites, the level of cysteinyl-leukotrienes in the ischemic brain was substantially increased 3 h to 24 h, near control at 3 days, and moderately increased again 7 days after reperfusion; whereas the level of LTB(4) was increased mildly 3 h but substantially 7-14 days after reperfusion. cysteinyl-leukotriene 35-57 arachidonate 5-lipoxygenase Rattus norvegicus 3-8 17063752-2 2006 Leukotriene C4 synthase (LTC4S) is the critical terminal pathway enzyme involved in regulation of cysteinyl leukotriene (CysLT) synthesis. cysteinyl-leukotriene 98-119 leukotriene C4 synthase Homo sapiens 25-30 17063752-2 2006 Leukotriene C4 synthase (LTC4S) is the critical terminal pathway enzyme involved in regulation of cysteinyl leukotriene (CysLT) synthesis. cysteinyl-leukotriene 121-126 leukotriene C4 synthase Homo sapiens 0-23 17063752-2 2006 Leukotriene C4 synthase (LTC4S) is the critical terminal pathway enzyme involved in regulation of cysteinyl leukotriene (CysLT) synthesis. cysteinyl-leukotriene 121-126 leukotriene C4 synthase Homo sapiens 25-30 16875498-0 2006 Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma. cysteinyl-leukotriene 0-22 adrenoceptor beta 2 Homo sapiens 44-62 16920908-0 2006 Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. cysteinyl-leukotriene 92-113 interleukin 4 Mus musculus 14-27 16920908-2 2006 RM fails to develop in mice lacking leukotriene (LT) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production. cysteinyl-leukotriene 96-117 leukotriene C4 synthase Mus musculus 36-64 16920908-2 2006 RM fails to develop in mice lacking leukotriene (LT) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production. cysteinyl-leukotriene 96-117 leukotriene C4 synthase Mus musculus 66-71 16867057-9 2006 Concentrations of both cys-LTs [205.4 pg/ml (65.5-472.3) with ECoScreen vs 21.6 (11.87-152.2) with RTube, P < 0.001] and eotaxin [17.0 pg/ml (11.4-22.4) with ECoScreen vs 11.7 (10.5-13.5) with RTube, P = 0.01] were significantly higher in samples collected with ECoScreen than with RTube. cysteinyl-leukotriene 23-30 C-C motif chemokine ligand 11 Homo sapiens 124-131 16583357-1 2006 In aspirin-intolerant subjects, adverse bronchial and nasal reactions to cyclooxygenase (COX) inhibitors are associated with over-production of cysteinyl-leukotrienes (cys-LTs) generated by the 5-lipoxygenase (5-LO) pathway. cysteinyl-leukotriene 144-166 arachidonate 5-lipoxygenase Homo sapiens 194-208 16756959-1 2006 Cysteinyl leukotrienes are involved in ischemic brain injury, and their receptors (CysLT(1) and CysLT(2)) have been cloned. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Rattus norvegicus 83-91 16756959-1 2006 Cysteinyl leukotrienes are involved in ischemic brain injury, and their receptors (CysLT(1) and CysLT(2)) have been cloned. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Rattus norvegicus 96-105 16475938-4 2006 Furthermore, non-P2Y GPCRs, the cysteinylleukotriene receptors (CysLT1R and CysLT2R) have been described to be activated by UDP in addition to activation by cysteinylleukotrienes. cysteinyl-leukotriene 157-178 cysteinyl leukotriene receptor 2 Homo sapiens 76-83 16776674-1 2006 BACKGROUND: The cysteinyl-leukotriene receptor type 1 (CysLT1) mediates the bronchoconstrictor and pro-inflammatory actions of cysteinyl-leukotrienes (LTC4, LTD4, LTE4) in asthma and is the molecular target of the lukast class of oral anti-leukotriene drugs. cysteinyl-leukotriene 127-149 cysteinyl leukotriene receptor 1 Homo sapiens 16-53 16776674-1 2006 BACKGROUND: The cysteinyl-leukotriene receptor type 1 (CysLT1) mediates the bronchoconstrictor and pro-inflammatory actions of cysteinyl-leukotrienes (LTC4, LTD4, LTE4) in asthma and is the molecular target of the lukast class of oral anti-leukotriene drugs. cysteinyl-leukotriene 127-149 cysteinyl leukotriene receptor 1 Homo sapiens 55-61 16771777-1 2006 Pharmacologic studies have revealed that cysteinyl leukotrienes (CYSLTs) act through two receptors, cysteinyl leukotriene receptor 1 (CYSLTR1) and CYSLTR2. cysteinyl-leukotriene 41-63 cysteinyl leukotriene receptor 1 Homo sapiens 100-132 16771777-1 2006 Pharmacologic studies have revealed that cysteinyl leukotrienes (CYSLTs) act through two receptors, cysteinyl leukotriene receptor 1 (CYSLTR1) and CYSLTR2. cysteinyl-leukotriene 41-63 cysteinyl leukotriene receptor 1 Homo sapiens 134-141 16771777-1 2006 Pharmacologic studies have revealed that cysteinyl leukotrienes (CYSLTs) act through two receptors, cysteinyl leukotriene receptor 1 (CYSLTR1) and CYSLTR2. cysteinyl-leukotriene 41-63 cysteinyl leukotriene receptor 2 Homo sapiens 147-154 16606835-1 2006 Cysteinyl leukotrienes (cysLT), i.e., LTC4, LTD4, and LTE4, are lipid mediators derived from the 5-lipoxygenase pathway, and the cysLT receptors cysLT1-R/cysLT2-R mediate inflammatory tissue reactions. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 97-111 16606835-1 2006 Cysteinyl leukotrienes (cysLT), i.e., LTC4, LTD4, and LTE4, are lipid mediators derived from the 5-lipoxygenase pathway, and the cysLT receptors cysLT1-R/cysLT2-R mediate inflammatory tissue reactions. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 145-153 16606835-1 2006 Cysteinyl leukotrienes (cysLT), i.e., LTC4, LTD4, and LTE4, are lipid mediators derived from the 5-lipoxygenase pathway, and the cysLT receptors cysLT1-R/cysLT2-R mediate inflammatory tissue reactions. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 154-162 16415251-3 2006 5-lipoxygenase (5-LO) is the rate-limiting enzyme in the synthetic pathway for cysteinyl leukotrienes (CysLTs), bronchoconstricting agents that are overproduced in asthma. cysteinyl-leukotriene 79-101 arachidonate 5-lipoxygenase Homo sapiens 0-14 16475938-4 2006 Furthermore, non-P2Y GPCRs, the cysteinylleukotriene receptors (CysLT1R and CysLT2R) have been described to be activated by UDP in addition to activation by cysteinylleukotrienes. cysteinyl-leukotriene 157-178 cysteinyl leukotriene receptor 1 Homo sapiens 64-71 16474098-7 2006 GM-CSF-/- mice are defective in the production of cysteinyl leukotrienes, prostaglandin E2, macrophage inflammatory protein, and keratinocyte-derived chemokine in lung leukocytes postinfection. cysteinyl-leukotriene 50-72 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 0-6 16579869-2 2006 NSAID-induced reactions appear to be caused by the inhibition of cyclooxygenase-1 (Cox-1); this in turn activates the lipoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs) that induces bronchospasm and nasal obstruction. cysteinyl-leukotriene 182-204 prostaglandin-endoperoxide synthase 1 Homo sapiens 65-81 16579869-2 2006 NSAID-induced reactions appear to be caused by the inhibition of cyclooxygenase-1 (Cox-1); this in turn activates the lipoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs) that induces bronchospasm and nasal obstruction. cysteinyl-leukotriene 182-204 prostaglandin-endoperoxide synthase 1 Homo sapiens 83-88 16579869-2 2006 NSAID-induced reactions appear to be caused by the inhibition of cyclooxygenase-1 (Cox-1); this in turn activates the lipoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs) that induces bronchospasm and nasal obstruction. cysteinyl-leukotriene 206-213 prostaglandin-endoperoxide synthase 1 Homo sapiens 65-81 16579869-2 2006 NSAID-induced reactions appear to be caused by the inhibition of cyclooxygenase-1 (Cox-1); this in turn activates the lipoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs) that induces bronchospasm and nasal obstruction. cysteinyl-leukotriene 206-213 prostaglandin-endoperoxide synthase 1 Homo sapiens 83-88 16630147-1 2006 BACKGROUND: Cysteinyl leukotrienes (CysLTs) play important roles in the pathogenesis of eosinophilic airway inflammation characterized by bronchoconstriction, mucus secretion and airway hyper-responsiveness via cysteinyl leukotriene receptor 1 (CysLTR1)-mediated mechanism. cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Homo sapiens 211-243 16630147-1 2006 BACKGROUND: Cysteinyl leukotrienes (CysLTs) play important roles in the pathogenesis of eosinophilic airway inflammation characterized by bronchoconstriction, mucus secretion and airway hyper-responsiveness via cysteinyl leukotriene receptor 1 (CysLTR1)-mediated mechanism. cysteinyl-leukotriene 12-34 cysteinyl leukotriene receptor 1 Homo sapiens 245-252 16630147-1 2006 BACKGROUND: Cysteinyl leukotrienes (CysLTs) play important roles in the pathogenesis of eosinophilic airway inflammation characterized by bronchoconstriction, mucus secretion and airway hyper-responsiveness via cysteinyl leukotriene receptor 1 (CysLTR1)-mediated mechanism. cysteinyl-leukotriene 36-42 cysteinyl leukotriene receptor 1 Homo sapiens 211-243 16630147-1 2006 BACKGROUND: Cysteinyl leukotrienes (CysLTs) play important roles in the pathogenesis of eosinophilic airway inflammation characterized by bronchoconstriction, mucus secretion and airway hyper-responsiveness via cysteinyl leukotriene receptor 1 (CysLTR1)-mediated mechanism. cysteinyl-leukotriene 36-42 cysteinyl leukotriene receptor 1 Homo sapiens 245-252 16505607-2 2006 RECENT FINDINGS: The overproduction of cysteinyl leukotrienes with the increased expression of cysteinyl leukotriene receptor 1 (CYSLTR1) is a consistent finding in aspirin-induced asthma patients. cysteinyl-leukotriene 39-61 cysteinyl leukotriene receptor 1 Homo sapiens 95-127 16505607-2 2006 RECENT FINDINGS: The overproduction of cysteinyl leukotrienes with the increased expression of cysteinyl leukotriene receptor 1 (CYSLTR1) is a consistent finding in aspirin-induced asthma patients. cysteinyl-leukotriene 39-61 cysteinyl leukotriene receptor 1 Homo sapiens 129-136 16374165-8 2006 All events were abolished when formation of cysteinyl-leukotrienes was blocked by the 5-lipoxygenase activity inhibitor MK-886, targeting 5-lipoxygenase activating protein. cysteinyl-leukotriene 44-66 arachidonate 5-lipoxygenase Rattus norvegicus 86-100 16374165-8 2006 All events were abolished when formation of cysteinyl-leukotrienes was blocked by the 5-lipoxygenase activity inhibitor MK-886, targeting 5-lipoxygenase activating protein. cysteinyl-leukotriene 44-66 arachidonate 5-lipoxygenase Rattus norvegicus 138-152 16272346-9 2005 Levels of PGE2 were reduced in COX-1-/- airways whereas cysteinyl leukotrienes were elevated in COX-2-/- airways following infection. cysteinyl-leukotriene 56-78 cytochrome c oxidase II, mitochondrial Mus musculus 96-101 17153879-1 2006 BACKGROUND: The cysteinyl leukotrienes (cys-LTs) are proinflammatory mediators synthesized through the 5-lipoxygenase pathway of arachidonic acid metabolism. cysteinyl-leukotriene 16-38 arachidonate 5-lipoxygenase Homo sapiens 103-117 17153879-1 2006 BACKGROUND: The cysteinyl leukotrienes (cys-LTs) are proinflammatory mediators synthesized through the 5-lipoxygenase pathway of arachidonic acid metabolism. cysteinyl-leukotriene 40-47 arachidonate 5-lipoxygenase Homo sapiens 103-117 17153879-2 2006 Cys-LTs exert their biological action by binding two types of G-protein-coupled seven transmembrane receptors, CYSLTR1 and CYSLTR2. cysteinyl-leukotriene 0-7 cysteinyl leukotriene receptor 1 Homo sapiens 111-118 17153879-2 2006 Cys-LTs exert their biological action by binding two types of G-protein-coupled seven transmembrane receptors, CYSLTR1 and CYSLTR2. cysteinyl-leukotriene 0-7 cysteinyl leukotriene receptor 2 Homo sapiens 123-130 16337471-4 2005 RESULTS: Exposure to IgE, but not IgG, at concentrations as low as 2.5 microg/mL significantly enhanced the release of IL-8 and monocyte chemoattractant protein 1, but not histamine or cysteinyl leukotrienes. cysteinyl-leukotriene 185-207 immunoglobulin heavy constant epsilon Homo sapiens 21-24 16445567-0 2005 Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery. cysteinyl-leukotriene 0-22 arginine vasopressin Rattus norvegicus 78-89 16445567-3 2005 The present study addresses the role of 5-lipoxygenase and its products, namely cysteinyl leukotrienes (CysLTs) and leukotriene (LT) B4, in the contraction induced by AVP in rat basilar artery. cysteinyl-leukotriene 80-102 arachidonate 5-lipoxygenase Rattus norvegicus 40-54 16445567-3 2005 The present study addresses the role of 5-lipoxygenase and its products, namely cysteinyl leukotrienes (CysLTs) and leukotriene (LT) B4, in the contraction induced by AVP in rat basilar artery. cysteinyl-leukotriene 104-110 arachidonate 5-lipoxygenase Rattus norvegicus 40-54 16185654-2 2005 The in silico screening using the docking software AutoDock resulted in selection of cysteinylleukotrienes (CysLTs) and 5-phosphoribosyl 1-pyrophosphate (PRPP), with high free energy changes, in addition to the known P2Y12 ligands such as 2MeSADP and ADP. cysteinyl-leukotriene 85-106 purinergic receptor P2Y12 Homo sapiens 217-222 16185654-2 2005 The in silico screening using the docking software AutoDock resulted in selection of cysteinylleukotrienes (CysLTs) and 5-phosphoribosyl 1-pyrophosphate (PRPP), with high free energy changes, in addition to the known P2Y12 ligands such as 2MeSADP and ADP. cysteinyl-leukotriene 108-114 purinergic receptor P2Y12 Homo sapiens 217-222 16101934-10 2005 RSV infection also is associated with synergizing LT biosynthesis and this study demonstrated ECP in NPA was significantly correlated with urinary LTE(4) and may suggest that cysteinyl leukotriene initiate the production of ECP in early childhood, which could contribute to the development of wheeze. cysteinyl-leukotriene 175-196 ribonuclease A family member 3 Homo sapiens 94-97 16171799-3 2005 Previously, we showed that a PPARgamma agonist, troglitazone, inhibited cysteinyl (Cys)-leukotrienes production in RBL-2H3 cells after IgE receptor triggering. cysteinyl-leukotriene 72-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-38 16171799-5 2005 A PPARgamma agonist, ciglitazone, significantly inhibited Cys-leukotrienes, but not prostaglandin D2, production. cysteinyl-leukotriene 58-74 peroxisome proliferator-activated receptor gamma Rattus norvegicus 2-11 16171799-8 2005 These results suggest that the inhibition by PPARgamma agonists of Cys-leukotrienes production in RBL-2H3 cells after IgE receptor triggering is not through the activation of PPARgamma. cysteinyl-leukotriene 67-83 peroxisome proliferator-activated receptor gamma Rattus norvegicus 45-54 16164450-0 2005 Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. cysteinyl-leukotriene 0-22 C-C motif chemokine ligand 2 Homo sapiens 30-64 15953562-9 2005 In conclusion, our findings show that IL-13 causes a long-term exacerbation of the IgE-mediated eosinophilic response in a mechanism associated with heightened cysteinyl-leukotriene (cys-LT) production by resident mast cells. cysteinyl-leukotriene 160-181 interleukin 13 Rattus norvegicus 38-43 16101934-10 2005 RSV infection also is associated with synergizing LT biosynthesis and this study demonstrated ECP in NPA was significantly correlated with urinary LTE(4) and may suggest that cysteinyl leukotriene initiate the production of ECP in early childhood, which could contribute to the development of wheeze. cysteinyl-leukotriene 175-196 ribonuclease A family member 3 Homo sapiens 224-227 15557087-3 2005 However, growing evidence raises the possibility that in airways and asthma-related inflammatory cells (eosinophils, basophils), the production of the bronchoconstrictor cysteinyl leukotrienes (CysLT) is linked exclusively to sPLA2, whereas the bronchodilator prostaglandin PGE2 is produced by cPLA2. cysteinyl-leukotriene 170-192 phospholipase A2 group IIA Rattus norvegicus 226-231 16027259-7 2005 Measurement of urinary metabolites of vasoactive molecules showed that cysteinyl leukotrienes, prostacyclin metabolites, and PGE2 were all increased to a similar degree in both BMPR2(+/-) and wild-type mice during 5LO transgene expression, whereas urinary endothelin-1 remained undetectable. cysteinyl-leukotriene 71-93 bone morphogenetic protein receptor, type II (serine/threonine kinase) Mus musculus 177-182 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 112-133 arachidonate 5-lipoxygenase Homo sapiens 29-34 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 112-133 arachidonate 5-lipoxygenase Homo sapiens 40-54 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 112-133 arachidonate 5-lipoxygenase activating protein Homo sapiens 75-82 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 135-141 arachidonate 5-lipoxygenase Homo sapiens 29-34 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 135-141 arachidonate 5-lipoxygenase Homo sapiens 40-54 15876305-1 2005 BACKGROUND: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). cysteinyl-leukotriene 135-141 arachidonate 5-lipoxygenase activating protein Homo sapiens 75-82 16002666-5 2005 Upon binding to the 5(S)-hydroxy-6(R)-S-cysteinylglycyl-7,9-trans-11,14-cis-eicosatetraenoic acid (LTD(4)) cysteinyl leukotriene, CysLT(1) induced Ca(2+) flux and caused chemotaxis in both LatY136F alphabeta and Lat3YF gammadelta T cells. cysteinyl-leukotriene 107-128 cysteinyl leukotriene receptor 1 Mus musculus 130-137 15590629-1 2005 Cysteinyl leukotrienes activate the cysteinyl leukotriene type 1 receptor (CysLT1R) to regulate numerous cell functions important in inflammatory processes and diseases such as asthma. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 36-73 15590629-1 2005 Cysteinyl leukotrienes activate the cysteinyl leukotriene type 1 receptor (CysLT1R) to regulate numerous cell functions important in inflammatory processes and diseases such as asthma. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 75-82 15557087-3 2005 However, growing evidence raises the possibility that in airways and asthma-related inflammatory cells (eosinophils, basophils), the production of the bronchoconstrictor cysteinyl leukotrienes (CysLT) is linked exclusively to sPLA2, whereas the bronchodilator prostaglandin PGE2 is produced by cPLA2. cysteinyl-leukotriene 170-192 phospholipase A2 group IVA Rattus norvegicus 294-299 15696087-9 2005 CONCLUSION: Although cysLT 1 expression predominates on inflammatory leukocytes in patients with aspirin-sensitive rhinosinusitis, the effects of cysteinyl leukotrienes on glands and epithelium may be mediated predominantly through cysLT 2. cysteinyl-leukotriene 146-168 cysteinyl leukotriene receptor 2 Homo sapiens 232-239 15378764-6 2004 Moreover, the concentrations of cysteinyl leukotrienes in bronchoalveolar lavage fluid and of leukotriene B(4) in lung tissue were increased by ovalbumin challenge in a NAC- or selenite-sensitive manner. cysteinyl-leukotriene 32-54 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 144-153 16301808-2 2005 In order to elucidate the role played by the complement split products, anaphylatoxins C3a and C5a, we evaluated their effects on production of cysteinyl-leukotrienes (cysLTs) by human lung fragments following an anaphylactic reaction. cysteinyl-leukotriene 144-166 complement C5a receptor 1 Homo sapiens 95-98 15947480-3 2005 Since massive eosinophil infiltration and the release of cysteinyl leukotrienes in airway secretions are often seen in asthma, we hypothesized that cysteinyl leukotrienes may be involved in airway remodeling through induction of TGF-beta1 from eosinophils. cysteinyl-leukotriene 148-170 transforming growth factor beta 1 Homo sapiens 229-238 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 56-78 cysteinyl leukotriene receptor 1 Mus musculus 117-149 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 56-78 cysteinyl leukotriene receptor 1 Mus musculus 151-158 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 56-78 cysteinyl leukotriene receptor 2 Mus musculus 164-196 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 56-78 cysteinyl leukotriene receptor 2 Mus musculus 198-205 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 80-86 cysteinyl leukotriene receptor 1 Mus musculus 117-149 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 80-86 cysteinyl leukotriene receptor 1 Mus musculus 151-158 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 80-86 cysteinyl leukotriene receptor 2 Mus musculus 164-196 15545522-1 2004 BACKGROUND: The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). cysteinyl-leukotriene 80-86 cysteinyl leukotriene receptor 2 Mus musculus 198-205 15242876-4 2004 Cross-linking of LIR7 resulted in the concentration-dependent net release of histamine (29.8 +/- 10.8%) and cysteinyl leukotrienes (cysLTs) (31.4 +/- 8.7 ng/10(6) basophils) that were maximal at 30 minutes, and of interleukin-4 (IL-4) (410.2 +/- 61.6 pg/10(6) basophils) that was maximal at 4 hours and comparable with the response initiated by cross-linking of the high-affinity receptor for immunoglobulin E (FcepsilonRI). cysteinyl-leukotriene 108-130 leukocyte immunoglobulin like receptor A2 Homo sapiens 17-21 15242876-4 2004 Cross-linking of LIR7 resulted in the concentration-dependent net release of histamine (29.8 +/- 10.8%) and cysteinyl leukotrienes (cysLTs) (31.4 +/- 8.7 ng/10(6) basophils) that were maximal at 30 minutes, and of interleukin-4 (IL-4) (410.2 +/- 61.6 pg/10(6) basophils) that was maximal at 4 hours and comparable with the response initiated by cross-linking of the high-affinity receptor for immunoglobulin E (FcepsilonRI). cysteinyl-leukotriene 132-138 leukocyte immunoglobulin like receptor A2 Homo sapiens 17-21 15530365-1 2004 Leukotriene (LT) C(4) synthase, an 18 kDa integral membrane enzyme, conjugates LTA(4) with reduced glutathione to form LTC(4), the parent compound of all cysteinyl leukotrienes that play a crucial role in the pathobiology of bronchial asthma. cysteinyl-leukotriene 154-176 leukotriene C4 synthase Homo sapiens 0-30 14561150-10 2003 SCF induced long-lived airway hyperreactivity, which was prevented by local neutralization of SCF, as well as by inhibitors of the production or activity of cysteinyl-leukotrienes. cysteinyl-leukotriene 157-179 KIT ligand Homo sapiens 0-3 15328359-1 2004 The cysteinyl leukotrienes (cys-LTs) mediate both acute and chronic inflammatory responses in mice, as demonstrated by the attenuation of the IgE/antigen-mediated increase in microvascular permeability and of bleomycin-induced pulmonary fibrosis, respectively, in a strain with targeted disruption of leukotriene C(4) synthase to prevent cys-LT synthesis. cysteinyl-leukotriene 4-26 leukotriene C4 synthase Mus musculus 301-326 15328359-1 2004 The cysteinyl leukotrienes (cys-LTs) mediate both acute and chronic inflammatory responses in mice, as demonstrated by the attenuation of the IgE/antigen-mediated increase in microvascular permeability and of bleomycin-induced pulmonary fibrosis, respectively, in a strain with targeted disruption of leukotriene C(4) synthase to prevent cys-LT synthesis. cysteinyl-leukotriene 28-35 leukotriene C4 synthase Mus musculus 301-326 15328359-1 2004 The cysteinyl leukotrienes (cys-LTs) mediate both acute and chronic inflammatory responses in mice, as demonstrated by the attenuation of the IgE/antigen-mediated increase in microvascular permeability and of bleomycin-induced pulmonary fibrosis, respectively, in a strain with targeted disruption of leukotriene C(4) synthase to prevent cys-LT synthesis. cysteinyl-leukotriene 28-34 leukotriene C4 synthase Mus musculus 301-326 15379985-1 2004 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through a receptor (cysLT1-R) which can be targeted in rhinitis and asthma. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Mus musculus 111-119 15379985-1 2004 The cysteinyl leukotrienes (cysLTs) are potent lipid mediators in allergic disease, acting through a receptor (cysLT1-R) which can be targeted in rhinitis and asthma. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 1 Mus musculus 111-119 15355318-2 2004 In this report we have demonstrated that rat cultured astrocytes express the enzymes (5"-lipoxygenase and LTC(4) synthase) required for cys-LT production, and release cys-LTs in resting condition and, to a greater extent, in response to calcium ionophore A23187, 1 h combined oxygen-glucose deprivation or 2-methyl-thioATP, a selective P2Y(1)/ATP receptor agonist. cysteinyl-leukotriene 136-142 arachidonate 5-lipoxygenase Rattus norvegicus 86-101 15355318-2 2004 In this report we have demonstrated that rat cultured astrocytes express the enzymes (5"-lipoxygenase and LTC(4) synthase) required for cys-LT production, and release cys-LTs in resting condition and, to a greater extent, in response to calcium ionophore A23187, 1 h combined oxygen-glucose deprivation or 2-methyl-thioATP, a selective P2Y(1)/ATP receptor agonist. cysteinyl-leukotriene 136-142 leukotriene C4 synthase Rattus norvegicus 106-121 15260484-11 2004 Kinetic and photolabeling studies revealed that mutation N590A not only decreased the affinity of MRP1 for cysteinyl leukotriene 4 (LTC(4)) but also substantially reduced the binding of ATP to nucleotide binding domain 1 (NBD1). cysteinyl-leukotriene 107-128 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 15210825-0 2004 Rac and protein kinase C-delta regulate ERKs and cytosolic phospholipase A2 in FcepsilonRI signaling to cysteinyl leukotriene synthesis in mast cells. cysteinyl-leukotriene 104-125 Rac family small GTPase 1 Rattus norvegicus 0-3 15251228-1 2004 The metabolism of arachidonic acid via the 5-lipoxygenase enzymatic pathway leads to the formation of the cysteinyl-leukotrienes and lipoxins, which have been implicated in several inflammatory reactions. cysteinyl-leukotriene 106-128 arachidonate 5-lipoxygenase Homo sapiens 43-57 14761945-4 2004 Furthermore, the early phase of plasma exudation in response to intraperitoneal injection of zymosan and the accompanying in vivo generation of cysteinyl leukotrienes were markedly attenuated in group V sPLA2-null mice compared with wild-type controls. cysteinyl-leukotriene 144-166 phospholipase A2, group V Mus musculus 203-208 15482000-8 2004 The shunting hypothesis proposes that inhibition of COX-1 shunts AA metabolism away from production of protective prostanoids and towards cysteinyl leukotriene (cys-LT) biosynthesis, resulting in bronchoconstriction and increased mucus production. cysteinyl-leukotriene 138-159 mitochondrially encoded cytochrome c oxidase I Homo sapiens 52-57 15482000-8 2004 The shunting hypothesis proposes that inhibition of COX-1 shunts AA metabolism away from production of protective prostanoids and towards cysteinyl leukotriene (cys-LT) biosynthesis, resulting in bronchoconstriction and increased mucus production. cysteinyl-leukotriene 161-167 mitochondrially encoded cytochrome c oxidase I Homo sapiens 52-57 15145787-5 2004 Leptin pretreatment of either rat alveolar or murine peritoneal macrophages for 16 h dose dependently increased the synthesis of leukotriene B4 and cysteinyl leukotrienes in response to calcium ionophore or the particulate zymosan. cysteinyl-leukotriene 148-170 leptin Rattus norvegicus 0-6 15265876-1 2004 The cysteinyl leukotrienes (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT(1) and CysLT(2) receptors. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Mus musculus 161-169 15265876-1 2004 The cysteinyl leukotrienes (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT(1) and CysLT(2) receptors. cysteinyl-leukotriene 28-35 cysteinyl leukotriene receptor 1 Mus musculus 161-169 15056404-1 2004 Cysteinyl leukotrienes (CysLTs) mediate their biologic activities through interactions with the CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 96-102 15056404-1 2004 Cysteinyl leukotrienes (CysLTs) mediate their biologic activities through interactions with the CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 107-113 15056404-1 2004 Cysteinyl leukotrienes (CysLTs) mediate their biologic activities through interactions with the CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 96-102 15056404-1 2004 Cysteinyl leukotrienes (CysLTs) mediate their biologic activities through interactions with the CysLT1 and CysLT2 receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 2 Homo sapiens 107-113 14637132-1 2003 The committed step in the biosynthesis of cysteinyl-leukotrienes is catalyzed by leukotriene C(4) synthase as well as microsomal glutathione S-transferase (MGST) type 2 and type 3, which belong to a family of membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). cysteinyl-leukotriene 42-64 leukotriene C4 synthase Rattus norvegicus 81-106 12878209-0 2003 Expression of leukotriene C4 synthase mRNA by the choroid plexus in mouse brain suggests novel neurohormone functions of cysteinyl leukotrienes. cysteinyl-leukotriene 121-143 leukotriene C4 synthase Mus musculus 14-37 13679572-0 2003 Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. cysteinyl-leukotriene 38-60 cysteinyl leukotriene receptor 2 Homo sapiens 62-69 13679572-1 2003 Cysteinyl leukotrienes (cysLTs) mediate vascular leakage and bronchoconstriction through the smooth muscle-associated CysLT type 1 receptor (CysLT1R), one of at least two loosely homologous cysLT-binding G protein-coupled receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 118-139 13679572-1 2003 Cysteinyl leukotrienes (cysLTs) mediate vascular leakage and bronchoconstriction through the smooth muscle-associated CysLT type 1 receptor (CysLT1R), one of at least two loosely homologous cysLT-binding G protein-coupled receptors. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 141-148 13679572-1 2003 Cysteinyl leukotrienes (cysLTs) mediate vascular leakage and bronchoconstriction through the smooth muscle-associated CysLT type 1 receptor (CysLT1R), one of at least two loosely homologous cysLT-binding G protein-coupled receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 118-139 13679572-1 2003 Cysteinyl leukotrienes (cysLTs) mediate vascular leakage and bronchoconstriction through the smooth muscle-associated CysLT type 1 receptor (CysLT1R), one of at least two loosely homologous cysLT-binding G protein-coupled receptors. cysteinyl-leukotriene 24-30 cysteinyl leukotriene receptor 1 Homo sapiens 141-148 13679572-4 2003 The selective function of CysLT2R was evident based on uninhibited IL-8 secretion by IL-4-primed hMCs stimulated with cys-LTs or UDP in the presence of the selective CysLT1R antagonist MK571. cysteinyl-leukotriene 118-125 cysteinyl leukotriene receptor 2 Homo sapiens 26-33 13679572-7 2003 The CysLT2 response may permit the cys-LTs and nucleotides generated in infection and tissue injury to elicit IL-8 generation by hMCs, potentially leading to neutrophilic infiltration, a characteristic of aerosol challenge-induced late-phase responses and of sudden death associated with asthma. cysteinyl-leukotriene 35-42 cysteinyl leukotriene receptor 2 Homo sapiens 4-10 13679572-7 2003 The CysLT2 response may permit the cys-LTs and nucleotides generated in infection and tissue injury to elicit IL-8 generation by hMCs, potentially leading to neutrophilic infiltration, a characteristic of aerosol challenge-induced late-phase responses and of sudden death associated with asthma. cysteinyl-leukotriene 35-42 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 13679572-7 2003 The CysLT2 response may permit the cys-LTs and nucleotides generated in infection and tissue injury to elicit IL-8 generation by hMCs, potentially leading to neutrophilic infiltration, a characteristic of aerosol challenge-induced late-phase responses and of sudden death associated with asthma. cysteinyl-leukotriene 35-42 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 129-133 14619337-1 2003 Important in the pathogenesis of asthma is the secretion of interleukin (IL)-5 by allergen-specific TH2 cells, which augments eosinophil functions, as well as subsequent synthesis of cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 183-205 interleukin 5 Homo sapiens 60-78 14619337-1 2003 Important in the pathogenesis of asthma is the secretion of interleukin (IL)-5 by allergen-specific TH2 cells, which augments eosinophil functions, as well as subsequent synthesis of cysteinyl leukotrienes (CysLTs). cysteinyl-leukotriene 207-213 interleukin 5 Homo sapiens 60-78 14515063-2 2003 The gene encoding the cysteinyl leukotriene 2 (CysLT2) receptor has been implicated in atopy since it is localized to a region of chromosome 13q14 that has been linked to atopy in several populations and the cysteinyl leukotrienes are known to activate eosinophils and mast cells in atopy. cysteinyl-leukotriene 208-230 cysteinyl leukotriene receptor 2 Homo sapiens 22-45 14515063-2 2003 The gene encoding the cysteinyl leukotriene 2 (CysLT2) receptor has been implicated in atopy since it is localized to a region of chromosome 13q14 that has been linked to atopy in several populations and the cysteinyl leukotrienes are known to activate eosinophils and mast cells in atopy. cysteinyl-leukotriene 208-230 cysteinyl leukotriene receptor 2 Homo sapiens 47-53 12884301-5 2003 Hence, the dominant contribution of secretory granule amines to SCF-induced tissue swelling is the result of gp49B1-mediated inhibition of the production of cysteinyl leukotrienes by mast cells. cysteinyl-leukotriene 157-179 kit ligand Mus musculus 64-67 12911785-1 2003 BACKGROUND: 5-Lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) are essential for cysteinyl-leukotriene (cys-LT) production, critical mediators in asthma. cysteinyl-leukotriene 97-118 arachidonate 5-lipoxygenase Homo sapiens 12-26 12911785-1 2003 BACKGROUND: 5-Lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) are essential for cysteinyl-leukotriene (cys-LT) production, critical mediators in asthma. cysteinyl-leukotriene 97-118 arachidonate 5-lipoxygenase Homo sapiens 38-52 12911785-1 2003 BACKGROUND: 5-Lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) are essential for cysteinyl-leukotriene (cys-LT) production, critical mediators in asthma. cysteinyl-leukotriene 97-118 arachidonate 5-lipoxygenase activating protein Homo sapiens 73-77 12891383-2 2003 The LTC4S gene encodes for LTC(4) synthase, the terminal enzyme in the generation of cysteinyl-leukotrienes (cys-LTs), which are key mediators in the pathogenesis of asthma. cysteinyl-leukotriene 85-107 leukotriene C4 synthase Homo sapiens 4-9 12891383-2 2003 The LTC4S gene encodes for LTC(4) synthase, the terminal enzyme in the generation of cysteinyl-leukotrienes (cys-LTs), which are key mediators in the pathogenesis of asthma. cysteinyl-leukotriene 85-107 leukotriene C4 synthase Homo sapiens 27-42 12891383-2 2003 The LTC4S gene encodes for LTC(4) synthase, the terminal enzyme in the generation of cysteinyl-leukotrienes (cys-LTs), which are key mediators in the pathogenesis of asthma. cysteinyl-leukotriene 109-116 leukotriene C4 synthase Homo sapiens 4-9 12816881-0 2003 Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. cysteinyl-leukotriene 77-99 cysteinyl leukotriene receptor 2 Homo sapiens 27-33 12891383-2 2003 The LTC4S gene encodes for LTC(4) synthase, the terminal enzyme in the generation of cysteinyl-leukotrienes (cys-LTs), which are key mediators in the pathogenesis of asthma. cysteinyl-leukotriene 109-116 leukotriene C4 synthase Homo sapiens 27-42 12121194-4 2002 We aimed to compare urinary cysteinyl leukotriene (Cys-LT) levels during exacerbation and remission of AEDS in relation to clinical status, IgE levels, and eosinophil counts. cysteinyl-leukotriene 28-49 immunoglobulin heavy constant epsilon Homo sapiens 140-143 12895593-1 2003 LTC(4) synthase conjugates LTA(4) with glutathione (GSH) to form LTC(4), the parent compound of the cysteinyl leukotrienes. cysteinyl-leukotriene 100-122 leukotriene C4 synthase Homo sapiens 0-15 12895596-4 2003 As recently shown, eosinophils express CysLT1 and CysLT2, the only cloned receptors for cysteinyl leukotrienes. cysteinyl-leukotriene 88-110 cysteinyl leukotriene receptor 2 Homo sapiens 50-56 12767051-1 2003 Leukotriene C(4) synthase (LTC(4) S) is a pivotal enzyme for generation of cysteinyl-leukotrienes (cysLTs). cysteinyl-leukotriene 75-97 leukotriene C4 synthase Rattus norvegicus 0-25 12767051-1 2003 Leukotriene C(4) synthase (LTC(4) S) is a pivotal enzyme for generation of cysteinyl-leukotrienes (cysLTs). cysteinyl-leukotriene 75-97 leukotriene C4 synthase Rattus norvegicus 27-35 14552699-1 2003 Most adverse NSAID-induced respiratory and skin reactions appear to be precipitated by the inhibition of cyclooxygenase-1 (COX-1); this in turn activates the lypoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs). cysteinyl-leukotriene 222-244 prostaglandin-endoperoxide synthase 1 Homo sapiens 105-121 14552699-1 2003 Most adverse NSAID-induced respiratory and skin reactions appear to be precipitated by the inhibition of cyclooxygenase-1 (COX-1); this in turn activates the lypoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs). cysteinyl-leukotriene 222-244 prostaglandin-endoperoxide synthase 1 Homo sapiens 123-128 14552699-1 2003 Most adverse NSAID-induced respiratory and skin reactions appear to be precipitated by the inhibition of cyclooxygenase-1 (COX-1); this in turn activates the lypoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs). cysteinyl-leukotriene 246-253 prostaglandin-endoperoxide synthase 1 Homo sapiens 105-121 14552699-1 2003 Most adverse NSAID-induced respiratory and skin reactions appear to be precipitated by the inhibition of cyclooxygenase-1 (COX-1); this in turn activates the lypoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs). cysteinyl-leukotriene 246-253 prostaglandin-endoperoxide synthase 1 Homo sapiens 123-128 12897744-0 2003 Cysteinyl leukotrienes induce nuclear factor kappa b activation and RANTES production in a murine model of asthma. cysteinyl-leukotriene 0-22 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 30-52 12897744-0 2003 Cysteinyl leukotrienes induce nuclear factor kappa b activation and RANTES production in a murine model of asthma. cysteinyl-leukotriene 0-22 chemokine (C-C motif) ligand 5 Mus musculus 68-74 12832443-8 2003 Trypsin and the PAR2 agonist peptide were seen in trigger shape change, release of cysteinyl leukotrienes, and most obviously, generation of reactive oxygen species. cysteinyl-leukotriene 83-105 F2R like trypsin receptor 1 Homo sapiens 16-20 14592550-3 2003 Here we studied involvement of thromboxane (TX) A2, platelet activating factor (PAF) and cysteinyl leukotrienes (cysLTs) in the mechanisms of platelet-neutrophil adhesion that was induced by thrombin (10-100 mU/ml), fMLP (0.01-1 microM) or LPS (0.001-100 microg/ml). cysteinyl-leukotriene 89-111 coagulation factor II, thrombin Homo sapiens 191-199 12728163-1 2003 BACKGROUND: LTC4 synthase is essential for the production of cysteinyl leukotrienes (Cys-LT), critical mediators in asthma. cysteinyl-leukotriene 61-83 leukotriene C4 synthase Homo sapiens 12-25 12728163-1 2003 BACKGROUND: LTC4 synthase is essential for the production of cysteinyl leukotrienes (Cys-LT), critical mediators in asthma. cysteinyl-leukotriene 85-91 leukotriene C4 synthase Homo sapiens 12-25 12531730-0 2003 Cysteinyl leukotriene-dependent [Ca2+]i responses to angiotensin II in cardiomyocytes. cysteinyl-leukotriene 0-21 angiotensinogen Rattus norvegicus 53-67 12618517-5 2003 Migration and homing driven by FTY720, phosphorylated FTY720, or S1P also require 5-lipoxygenase-mediated synthesis of cysteinyl leukotrienes and their efflux from the cell. cysteinyl-leukotriene 119-141 arachidonate 5-lipoxygenase Homo sapiens 82-96 12615958-7 2003 The cysteinyl-leukotrienes (LT) activate another group called CysLT receptors, which are referred to as CysLT(1) and CysLT(2). cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Homo sapiens 104-112 12615958-7 2003 The cysteinyl-leukotrienes (LT) activate another group called CysLT receptors, which are referred to as CysLT(1) and CysLT(2). cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 2 Homo sapiens 117-125 12532090-8 2003 Strikingly, IL-4 induces an activation response by mast cells to cysteinyl leukotrienes, which act through a receptor shared with uridine diphosphate to induce cytokine generation without exocytosis. cysteinyl-leukotriene 65-87 interleukin 4 Homo sapiens 12-16 12376349-8 2002 Antigen-induced increases in cysteinyl leukotriene production in the lung were significantly reduced in the CGRP-disrupted mice. cysteinyl-leukotriene 29-50 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 108-112 12445492-1 2002 Leukotriene C(4) synthase (LTC(4) S) is considered a pivotal enzyme for generation of potent proinflammatory mediators, cysteinyl-leukotrienes (cysLTs). cysteinyl-leukotriene 120-142 leukotriene C4 synthase Rattus norvegicus 0-25 12445492-1 2002 Leukotriene C(4) synthase (LTC(4) S) is considered a pivotal enzyme for generation of potent proinflammatory mediators, cysteinyl-leukotrienes (cysLTs). cysteinyl-leukotriene 120-142 leukotriene C4 synthase Rattus norvegicus 27-35 12372129-8 2002 There was a significant correlation among the concentration of cys-LTs, the number of eosinophils and the concentration of eosinophil-derived neurotoxin (EDN) in sputum. cysteinyl-leukotriene 63-70 ribonuclease A family member 2 Homo sapiens 123-152 12372129-8 2002 There was a significant correlation among the concentration of cys-LTs, the number of eosinophils and the concentration of eosinophil-derived neurotoxin (EDN) in sputum. cysteinyl-leukotriene 63-70 ribonuclease A family member 2 Homo sapiens 154-157 12373000-1 2002 BACKGROUND: The cysteinyl leukotrienes (CysLTs) mediate their biological actions through two receptors: CysLT(1) receptor and CysLT(2) receptor. cysteinyl-leukotriene 16-38 cysteinyl leukotriene receptor 1 Homo sapiens 104-112 12373000-1 2002 BACKGROUND: The cysteinyl leukotrienes (CysLTs) mediate their biological actions through two receptors: CysLT(1) receptor and CysLT(2) receptor. cysteinyl-leukotriene 40-46 cysteinyl leukotriene receptor 1 Homo sapiens 104-112 12163373-3 2002 Here we show that in vivo GGL, and not GGT as previously believed, is primarily responsible for conversion of leukotriene C(4) to leukotriene D(4), the most potent of the cysteinyl leukotrienes and the immediate precursor of leukotriene E(4). cysteinyl-leukotriene 171-193 gamma-glutamyltransferase 5 Mus musculus 26-29 12121194-4 2002 We aimed to compare urinary cysteinyl leukotriene (Cys-LT) levels during exacerbation and remission of AEDS in relation to clinical status, IgE levels, and eosinophil counts. cysteinyl-leukotriene 51-57 immunoglobulin heavy constant epsilon Homo sapiens 140-143 12121194-11 2002 During AEDS exacerbation Cys-LTs levels were significantly correlated with the clinical status (rS = 0.73, P < 0.01) and with eosinophil counts (r = 0.86; P < 0.01) but not with the duration of the disease, age of patients, or IgE levels. cysteinyl-leukotriene 25-32 immunoglobulin heavy constant epsilon Homo sapiens 233-236 11438743-1 2001 The cysteinyl leukotrienes (cys-LTs) LTC(4), LTD(4), and LTE(4) are a class of peptide-conjugated lipids formed from arachidonic acid and released during activation of mast cells (MCs). cysteinyl-leukotriene 4-26 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 180-183 12063527-0 2002 Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. cysteinyl-leukotriene 0-22 interleukin 4 Homo sapiens 30-34 12063527-2 2002 OBJECTIVE: We evaluated whether cysteinyl leukotrienes (CysLTs) could elicit IL-4 release from eosinophils. cysteinyl-leukotriene 32-54 interleukin 4 Homo sapiens 77-81 12063527-2 2002 OBJECTIVE: We evaluated whether cysteinyl leukotrienes (CysLTs) could elicit IL-4 release from eosinophils. cysteinyl-leukotriene 56-62 interleukin 4 Homo sapiens 77-81 11877481-0 2002 Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. cysteinyl-leukotriene 0-22 interleukin 4 Homo sapiens 105-118 11877481-2 2002 We speculated that this IL-4-dependent, receptor-mediated response to the cys-LTs and UDP might induce cytokine generation by hMCs without concomitant exocytosis. cysteinyl-leukotriene 74-81 interleukin 4 Homo sapiens 24-28 11877481-2 2002 We speculated that this IL-4-dependent, receptor-mediated response to the cys-LTs and UDP might induce cytokine generation by hMCs without concomitant exocytosis. cysteinyl-leukotriene 74-81 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 126-130 11877481-4 2002 Cys-LT- and UDP-mediated cytokine production by the primed hMCs occurred without histamine release or PGD(2) generation and was inhibited by the CysLT1 receptor antagonist MK571. cysteinyl-leukotriene 0-6 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 59-63 11877481-4 2002 Cys-LT- and UDP-mediated cytokine production by the primed hMCs occurred without histamine release or PGD(2) generation and was inhibited by the CysLT1 receptor antagonist MK571. cysteinyl-leukotriene 0-6 cysteinyl leukotriene receptor 1 Homo sapiens 145-151 11877481-5 2002 Additionally, pretreatment of hMCs with MK571 or with the cys-LT biosynthetic inhibitor MK886 decreased IL-5 and TNF-alpha production in response to IgE receptor cross-linkage, implying a positive feedback by endogenously produced cys-LTs. cysteinyl-leukotriene 231-238 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 30-34 12185963-4 2002 Cysteinyl leukotrienes (5-lipoxygenase-derived products) and 12-hydroxyeicosatetraenoic acids (12-HETE) (12-lipoxygenase-derived products) are potent proinflammatory and vasomotor mediators. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 24-38 11832453-0 2002 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. cysteinyl-leukotriene 111-133 arachidonate 5-lipoxygenase Rattus norvegicus 0-14 12424566-10 2002 The biliary excretion of cysteinyl LTs was positively correlated with leukocyte concentration ( r = 0.68; P < 0.005) and C-reactive protein ( r = 0.73; P < 0.005) in blood. cysteinyl-leukotriene 25-38 C-reactive protein Homo sapiens 124-142 11898391-6 2002 Effective inhibitors of MRP1-mediated transport include structural analogs of LTC4 and of other cysteinyl leukotrienes. cysteinyl-leukotriene 96-118 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 11898391-7 2002 The ATP-dependent transport system which transports cysteinyl leukotrienes across the hepatocyte canalicular membrane into bile was cloned and characterized as the second isoform or paralog of the mammalian MRP family, MRP2 (ABC C2). cysteinyl-leukotriene 52-74 ATP binding cassette subfamily C member 2 Homo sapiens 219-223 11898391-7 2002 The ATP-dependent transport system which transports cysteinyl leukotrienes across the hepatocyte canalicular membrane into bile was cloned and characterized as the second isoform or paralog of the mammalian MRP family, MRP2 (ABC C2). cysteinyl-leukotriene 52-74 ATP binding cassette subfamily C member 2 Homo sapiens 225-231 11739134-1 2001 Cysteinyl-leukotrienes and prostaglandin D2 generated by the 5-lipoxygenase (5-LO) and cyclooxygenase (COX) pathways, respectively, cause bronchoconstriction, leukocyte recruitment, and bronchial hyperresponsiveness in asthma. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 61-75 12052325-1 2001 Arachidonic acid metabolism via 5-lipoxygenase gives rise to a group of biologically active lipids known as leukotrienes: leukotriene B(4), which is a potent activator of leukocyte chemotaxis, and cysteinyl leukotrienes (leukotriene C(4), D(4)and E(4)) which account for the spasmogenic activity previously described as slow-reacting substance of anaphylaxis. cysteinyl-leukotriene 197-219 arachidonate 5-lipoxygenase Homo sapiens 32-46 11574755-8 2001 Among OVA aerosol-challenged mice, the levels of interleukin-5 and cysteinyl leukotrienes in the bronchoalveolar lavage fluid were significantly higher in those fed the 2% cholesterol diet compared with mice on the control diet. cysteinyl-leukotriene 67-89 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 6-9 12432940-0 2002 Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes. cysteinyl-leukotriene 74-96 leukotriene C4 synthase Mus musculus 0-23 11994100-0 2002 Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 97-103 11821711-0 2002 Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats. cysteinyl-leukotriene 15-37 angiotensinogen Rattus norvegicus 41-55 11821711-1 2002 OBJECTIVES: We have previously reported that 5-lipoxygenase-derived products, and particularly the cysteinyl leukotrienes (CysLTs), were involved in angiotensin II (Ang II)-induced contractions in isolated aortas from spontaneously hypertensive rats. cysteinyl-leukotriene 99-121 angiotensinogen Rattus norvegicus 149-163 11821711-1 2002 OBJECTIVES: We have previously reported that 5-lipoxygenase-derived products, and particularly the cysteinyl leukotrienes (CysLTs), were involved in angiotensin II (Ang II)-induced contractions in isolated aortas from spontaneously hypertensive rats. cysteinyl-leukotriene 99-121 angiotensinogen Rattus norvegicus 165-171 11821711-1 2002 OBJECTIVES: We have previously reported that 5-lipoxygenase-derived products, and particularly the cysteinyl leukotrienes (CysLTs), were involved in angiotensin II (Ang II)-induced contractions in isolated aortas from spontaneously hypertensive rats. cysteinyl-leukotriene 123-129 angiotensinogen Rattus norvegicus 149-163 11821711-1 2002 OBJECTIVES: We have previously reported that 5-lipoxygenase-derived products, and particularly the cysteinyl leukotrienes (CysLTs), were involved in angiotensin II (Ang II)-induced contractions in isolated aortas from spontaneously hypertensive rats. cysteinyl-leukotriene 123-129 angiotensinogen Rattus norvegicus 165-171 12444802-7 2002 The prevalent theory about the pathogenesis of urticaria and angioedema due to NSAIDs in cross-reactive patients assumes that the inhibition of COX-1 leads to a shunting of arachidonic acid metabolism towards the 5-lipoxygenase pathway, which results in an increased synthesis and release of cysteinyl leukotrienes. cysteinyl-leukotriene 292-314 mitochondrially encoded cytochrome c oxidase I Homo sapiens 144-149 12444802-7 2002 The prevalent theory about the pathogenesis of urticaria and angioedema due to NSAIDs in cross-reactive patients assumes that the inhibition of COX-1 leads to a shunting of arachidonic acid metabolism towards the 5-lipoxygenase pathway, which results in an increased synthesis and release of cysteinyl leukotrienes. cysteinyl-leukotriene 292-314 arachidonate 5-lipoxygenase Homo sapiens 213-227 11591709-9 2001 Intracellular calcium mobilization in response to cysteinyl leukotriene administration was detected in human embryonic kidney 293T cells transfected with recombinant mCysLT(2)R with a rank order of potency leukotriene C(4)(LTC(4) ) = LTD(4)>>LTE(4). cysteinyl-leukotriene 50-71 cysteinyl leukotriene receptor 2 Mus musculus 166-176 11701461-0 2001 Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin-induced diabetic rats. cysteinyl-leukotriene 0-22 angiotensinogen Rattus norvegicus 32-46 11701461-2 2001 We have previously reported that the 5-lipoxygenase-derived products, particularly the cysteinyl leukotrienes (CysLTs), are involved in Ang II-induced contraction. cysteinyl-leukotriene 87-109 arachidonate 5-lipoxygenase Rattus norvegicus 37-51 11701461-2 2001 We have previously reported that the 5-lipoxygenase-derived products, particularly the cysteinyl leukotrienes (CysLTs), are involved in Ang II-induced contraction. cysteinyl-leukotriene 87-109 angiotensinogen Rattus norvegicus 136-142 11701461-2 2001 We have previously reported that the 5-lipoxygenase-derived products, particularly the cysteinyl leukotrienes (CysLTs), are involved in Ang II-induced contraction. cysteinyl-leukotriene 111-117 arachidonate 5-lipoxygenase Rattus norvegicus 37-51 11701461-2 2001 We have previously reported that the 5-lipoxygenase-derived products, particularly the cysteinyl leukotrienes (CysLTs), are involved in Ang II-induced contraction. cysteinyl-leukotriene 111-117 angiotensinogen Rattus norvegicus 136-142 11438743-1 2001 The cysteinyl leukotrienes (cys-LTs) LTC(4), LTD(4), and LTE(4) are a class of peptide-conjugated lipids formed from arachidonic acid and released during activation of mast cells (MCs). cysteinyl-leukotriene 28-35 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 180-183 11406502-0 2001 Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. cysteinyl-leukotriene 0-22 angiotensinogen Rattus norvegicus 60-74 11406502-1 2001 We assessed whether cysteinyl leukotrienes mediate the vasoconstrictor responses to angiotensin II and endothelin-1 in the mesenteric vascular bed of Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) perfused ex vivo at a constant flow rate of 5 ml/min with Krebs buffer. cysteinyl-leukotriene 20-42 angiotensinogen Rattus norvegicus 84-98 11406502-1 2001 We assessed whether cysteinyl leukotrienes mediate the vasoconstrictor responses to angiotensin II and endothelin-1 in the mesenteric vascular bed of Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) perfused ex vivo at a constant flow rate of 5 ml/min with Krebs buffer. cysteinyl-leukotriene 20-42 endothelin 1 Rattus norvegicus 103-115 11406502-6 2001 These data suggest that 5-lipoxygenase metabolites, particularly cysteinyl leukotrienes, contribute to the exaggerated vasoconstrictor responses to angiotensin II but not to endothelin-1. cysteinyl-leukotriene 65-87 arachidonate 5-lipoxygenase Rattus norvegicus 24-38 11438743-2 2001 We now report that human cord-blood-derived MCs (hMCs) express the CysLT1 receptor, which responds not only to inflammation-derived cys-LTs, but also to a pyrimidinergic ligand, UDP. cysteinyl-leukotriene 132-139 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 44-47 11406502-6 2001 These data suggest that 5-lipoxygenase metabolites, particularly cysteinyl leukotrienes, contribute to the exaggerated vasoconstrictor responses to angiotensin II but not to endothelin-1. cysteinyl-leukotriene 65-87 angiotensinogen Rattus norvegicus 148-162 11438743-2 2001 We now report that human cord-blood-derived MCs (hMCs) express the CysLT1 receptor, which responds not only to inflammation-derived cys-LTs, but also to a pyrimidinergic ligand, UDP. cysteinyl-leukotriene 132-139 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 49-53 11438743-2 2001 We now report that human cord-blood-derived MCs (hMCs) express the CysLT1 receptor, which responds not only to inflammation-derived cys-LTs, but also to a pyrimidinergic ligand, UDP. cysteinyl-leukotriene 132-139 cysteinyl leukotriene receptor 1 Homo sapiens 67-73 11438743-7 2001 hMCs thus express the CysLT1 receptor, and possibly a closely related IL-4-inducible receptor, which mediate dual activation responses to cys-LTs and UDP, providing an apparent intersection linking the inflammatory and neurogenic elements of bronchial asthma. cysteinyl-leukotriene 138-145 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 0-4 11438743-7 2001 hMCs thus express the CysLT1 receptor, and possibly a closely related IL-4-inducible receptor, which mediate dual activation responses to cys-LTs and UDP, providing an apparent intersection linking the inflammatory and neurogenic elements of bronchial asthma. cysteinyl-leukotriene 138-145 cysteinyl leukotriene receptor 1 Homo sapiens 22-28 11438743-7 2001 hMCs thus express the CysLT1 receptor, and possibly a closely related IL-4-inducible receptor, which mediate dual activation responses to cys-LTs and UDP, providing an apparent intersection linking the inflammatory and neurogenic elements of bronchial asthma. cysteinyl-leukotriene 138-145 interleukin 4 Homo sapiens 70-74 11467994-1 2001 BACKGROUND: Eosinophilopoetic cytokine IL-5 enhances cysteinyl-leukotriene (cys-LT) synthesis in eosinophils in vitro. cysteinyl-leukotriene 53-74 interleukin 5 Homo sapiens 39-43 11467994-1 2001 BACKGROUND: Eosinophilopoetic cytokine IL-5 enhances cysteinyl-leukotriene (cys-LT) synthesis in eosinophils in vitro. cysteinyl-leukotriene 76-82 interleukin 5 Homo sapiens 39-43 10887308-2 2000 These individuals typically have significant basal overproduction of cysteinyl leukotrienes, and within their biosynthetic pathway, the terminal enzyme, leukotriene C(4) synthase (LTC(4)S), is significantly overexpressed. cysteinyl-leukotriene 69-91 leukotriene C4 synthase Homo sapiens 153-178 11319240-1 2001 Leukotriene C(4) synthase (LTC(4)S), the terminal 5-lipoxygenase pathway enzyme that is responsible for the biosynthesis of cysteinyl leukotrienes, has been deleted by targeted gene disruption to define its tissue distribution and integrated pathway function in vitro and in vivo. cysteinyl-leukotriene 124-146 leukotriene C4 synthase Mus musculus 0-25 11319240-1 2001 Leukotriene C(4) synthase (LTC(4)S), the terminal 5-lipoxygenase pathway enzyme that is responsible for the biosynthesis of cysteinyl leukotrienes, has been deleted by targeted gene disruption to define its tissue distribution and integrated pathway function in vitro and in vivo. cysteinyl-leukotriene 124-146 leukotriene C4 synthase Mus musculus 27-34 11322876-6 2001 Moreover, HUVEC were found to express the CysLT1 receptor in line with a paracrine and autocrine role for cysteinyl-leukotrienes in endothelial cell function. cysteinyl-leukotriene 106-128 cysteinyl leukotriene receptor 1 Homo sapiens 42-48 11102445-9 2001 We found that estradiol and estrone 3-sulfate alone were poor competitors of MRP1-mediated transport of the cysteinyl leukotriene, leukotriene C(4). cysteinyl-leukotriene 108-129 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 11121807-0 2001 Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. cysteinyl-leukotriene 0-22 angiotensinogen Rattus norvegicus 39-53 11121807-2 2001 The aim of this study was to assess the role of cysteinyl leukotrienes, in the vascular response to angiotensin II in spontaneously hypertensive rats (SHR). cysteinyl-leukotriene 48-70 angiotensinogen Rattus norvegicus 100-114 11121807-6 2001 Angiotensin II induced a 8.6+/-2.1-fold increase in cysteinyl leukotriene production in aorta rings from SHR with endothelium which was prevented by the AT(1) receptor antagonist losartan 1 microM but not by the AT(2) receptor antagonist PD123319 0.1 microM. cysteinyl-leukotriene 52-73 angiotensinogen Rattus norvegicus 0-14 11121807-9 2001 CONCLUSIONS: These data suggest that cysteinyl leukotrienes, acting at least in part on endothelial CysLT(1) receptors, are involved in the contractile response to angiotensin II in isolated aorta from SHR but not from WKY. cysteinyl-leukotriene 37-59 angiotensinogen Rattus norvegicus 164-178 11136826-2 2001 As cysteinyl leukotriene (cys-LT) biosynthesis is a characteristic of immunoglobulin (Ig)E-activated mucosal hMCs, we speculated that Th2 cytokines might regulate eicosanoid generation by hMCs. cysteinyl-leukotriene 3-24 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 109-113 11136826-2 2001 As cysteinyl leukotriene (cys-LT) biosynthesis is a characteristic of immunoglobulin (Ig)E-activated mucosal hMCs, we speculated that Th2 cytokines might regulate eicosanoid generation by hMCs. cysteinyl-leukotriene 26-32 Miles-Carpenter X-linked mental retardation syndrome Homo sapiens 109-113 11085923-4 2000 Cross-linking of high-affinity receptors for IgE (FcepsilonRI) on cells from cPLA(-/-)(2) mice led to the release of negligible amounts of arachidonic acid or its metabolites, the cysteinyl leukotrienes and prostaglandin D(2), indicating an essential role for cPLA(2) in the production of these allergic and pro-inflammatory lipid mediators. cysteinyl-leukotriene 180-202 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 77-88 11029586-11 2000 Several nonsteroidal anti-inflammatory drugs, stable prostaglandin H2 analogues and cysteinyl leukotrienes were screened for inhibition of PGES activity. cysteinyl-leukotriene 84-106 prostaglandin E synthase Homo sapiens 139-143 10992553-0 2000 Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. cysteinyl-leukotriene 40-61 leukotriene C4 synthase Homo sapiens 8-23 10996024-0 2000 Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes. cysteinyl-leukotriene 134-156 complement C5 Rattus norvegicus 46-49 10946074-9 2000 Cysteinyl leukotrienes were released in response to angiotensin II (pg/mg dry weight tissue: 32+/-9 (basal, n=6) vs. 49+/-9 (angiotensin II 0.3 microM, n=6), P<0.05). cysteinyl-leukotriene 0-22 angiotensinogen Homo sapiens 52-66 10946074-9 2000 Cysteinyl leukotrienes were released in response to angiotensin II (pg/mg dry weight tissue: 32+/-9 (basal, n=6) vs. 49+/-9 (angiotensin II 0.3 microM, n=6), P<0.05). cysteinyl-leukotriene 0-22 angiotensinogen Homo sapiens 125-139 10946074-11 2000 CONCLUSIONS: This study suggests that the in vitro vasoconstrictor effects of angiotensin II in human internal mammary artery are enhanced at least in part by eicosanoids produced by the cyclooxygenase pathway, probably PGH(2), acting on TXA(2)/PGH(2) receptors, and by lipoxygenase-derived products, particularly cysteinyl leukotrienes acting on CysLT(1) receptors. cysteinyl-leukotriene 314-336 angiotensinogen Homo sapiens 78-92 11369634-4 2001 Cysteinyl leukotrienes, particularly leukotriene D4 (LTD4), induced strong intracellular calcium fluxes and actin polymerization in mobilized and BM CD34(+) progenitors. cysteinyl-leukotriene 0-22 CD34 molecule Homo sapiens 149-153 21336917-1 2001 The cysteinyl leukotrienes, comprising leukotriene (LT) C4 and its major metabolites LTD4 and LTE4, are inflammatory lipid mediators derived from metabolism of arachidonic acid by 5-lipoxygenase. cysteinyl-leukotriene 4-26 arachidonate 5-lipoxygenase Homo sapiens 180-194 11114332-4 2000 In vitro, these cysteinyl leukotrienes promoted optimal chemotaxis to the chemokine CCL19, but not to other related chemokines. cysteinyl-leukotriene 16-38 chemokine (C-C motif) ligand 19 Mus musculus 84-89 10887308-2 2000 These individuals typically have significant basal overproduction of cysteinyl leukotrienes, and within their biosynthetic pathway, the terminal enzyme, leukotriene C(4) synthase (LTC(4)S), is significantly overexpressed. cysteinyl-leukotriene 69-91 leukotriene C4 synthase Homo sapiens 180-187 10773010-0 2000 Role of cysteinyl leukotrienes in CD4(+) T cell-driven late allergic airway responses. cysteinyl-leukotriene 8-30 Cd4 molecule Rattus norvegicus 34-37 10729360-13 2000 These data strongly suggested the existence of two different mechanisms for the inhibition by PAK-104P of the MRP(1)-mediated efflux of molecules: a first mechanism, involving a low-affinity site for PAK-104P, and which would concern molecules such as calcein, cysteinyl leukotriene LCT(4) etc. cysteinyl-leukotriene 261-282 ATP binding cassette subfamily C member 1 Homo sapiens 110-115 10773025-2 2000 However, unlike P-glycoprotein, MRP1 is a primary active transporter of many conjugated organic anions, including the cysteinyl leukotriene LTC(4). cysteinyl-leukotriene 118-139 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 10722737-1 2000 Leukotriene C(4) synthase (LTC(4)S) is responsible for the biosynthesis of cysteinyl leukotrienes that participate in allergic and asthmatic inflammation. cysteinyl-leukotriene 75-97 leukotriene C4 synthase Homo sapiens 0-25 10722737-1 2000 Leukotriene C(4) synthase (LTC(4)S) is responsible for the biosynthesis of cysteinyl leukotrienes that participate in allergic and asthmatic inflammation. cysteinyl-leukotriene 75-97 leukotriene C4 synthase Homo sapiens 27-34 10669114-11 1999 In endotoxin-primed lungs, the COX-2 inhibitor NS-398 (0.3-1.0 microM) depressed basal as well as FMLP-stimulated release of 6-keto PGF1alpha, but did not cause a significant increase of LTB4 or cysteinyl-LT release. cysteinyl-leukotriene 195-207 cytochrome c oxidase II, mitochondrial Rattus norvegicus 31-36 10686285-1 2000 Cysteinyl leukotrienes (LTC(4), LTD(4), LTE(4)) are potent lipid mediators derived from arachidonate in the 5-lipoxygenase pathway. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 108-122 10804983-0 1999 Pranlukast, a cysteinyl leukotriene antagonist, reduces serum eosinophil cationic protein levels in patients with asthma. cysteinyl-leukotriene 14-35 ribonuclease A family member 3 Homo sapiens 62-89 10639007-1 1999 Two categories of cysteinyl-leukotrienes have been proposed, namely, CysLT1 and CysLT2. cysteinyl-leukotriene 18-40 cysteinyl leukotriene receptor 1 Homo sapiens 69-75 10639007-1 1999 Two categories of cysteinyl-leukotrienes have been proposed, namely, CysLT1 and CysLT2. cysteinyl-leukotriene 18-40 cysteinyl leukotriene receptor 2 Homo sapiens 80-86 10430730-0 1999 Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. cysteinyl-leukotriene 0-22 chemokine (C-C motif) ligand 11 Mus musculus 38-45 10497182-9 1999 Finally, in the presence of platelets (which contain LTC(4) synthase), the LTA(4) synthesized from exogenous deuterium-labeled arachidonate was converted to cys-LTs to a greater degree than that from endogenous sources. cysteinyl-leukotriene 157-164 leukotriene C4 synthase Homo sapiens 53-68 10430730-9 1999 We conclude that eotaxin-induced effects in the airways of IL-5 transgenic mice are partly mediated by the activation of 5-lipoxygenase enzyme leading to the generation of cysteinyl-leukotrienes. cysteinyl-leukotriene 172-194 chemokine (C-C motif) ligand 11 Mus musculus 17-24 10430730-9 1999 We conclude that eotaxin-induced effects in the airways of IL-5 transgenic mice are partly mediated by the activation of 5-lipoxygenase enzyme leading to the generation of cysteinyl-leukotrienes. cysteinyl-leukotriene 172-194 interleukin 5 Mus musculus 59-63 10430730-9 1999 We conclude that eotaxin-induced effects in the airways of IL-5 transgenic mice are partly mediated by the activation of 5-lipoxygenase enzyme leading to the generation of cysteinyl-leukotrienes. cysteinyl-leukotriene 172-194 arachidonate 5-lipoxygenase Mus musculus 121-135 10591082-1 1999 Leukotriene C4 (LTC4) synthase is an 18 kD integral membrane enzyme of the 5-lipoxygenase/LTC4 synthase pathway and is positioned as the pivotal and only committed enzyme for the formation of the cysteinyl leukotrienes. cysteinyl-leukotriene 196-218 arachidonate 5-lipoxygenase Homo sapiens 75-89 10591082-1 1999 Leukotriene C4 (LTC4) synthase is an 18 kD integral membrane enzyme of the 5-lipoxygenase/LTC4 synthase pathway and is positioned as the pivotal and only committed enzyme for the formation of the cysteinyl leukotrienes. cysteinyl-leukotriene 196-218 leukotriene C4 synthase Homo sapiens 90-103 10591082-8 1999 Immunohistochemical studies of mucosal biopsies from the bronchi of aspirin-intolerant asthmatics show that LTC4S is overrepresented in individuals with this phenotype, and this finding correlates with overproduction of cysteinyl leukotrienes and lysine-aspirin bronchial hyperreactivity. cysteinyl-leukotriene 220-242 leukotriene C4 synthase Homo sapiens 108-113 10462554-1 1999 The cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory disorders, in particular asthma, for which the CysLT receptor antagonists pranlukast, zafirlukast, and montelukast, have been introduced recently as novel therapeutics. cysteinyl-leukotriene 4-26 cysteinyl leukotriene receptor 1 Homo sapiens 143-157 10462554-1 1999 The cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory disorders, in particular asthma, for which the CysLT receptor antagonists pranlukast, zafirlukast, and montelukast, have been introduced recently as novel therapeutics. cysteinyl-leukotriene 28-34 cysteinyl leukotriene receptor 1 Homo sapiens 143-157 10430730-0 1999 Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. cysteinyl-leukotriene 0-22 interleukin 5 Mus musculus 104-108 10430730-2 1999 We determined whether these effects of eotaxin were mediated through the production of cysteinyl-leukotrienes. cysteinyl-leukotriene 87-109 chemokine (C-C motif) ligand 11 Mus musculus 39-46 10527888-1 1999 The human 5-lipoxygenase activating protein (FLAP) gene is one of the key genes involved in the production of the cysteinyl-leukotrienes. cysteinyl-leukotriene 114-136 arachidonate 5-lipoxygenase activating protein Homo sapiens 45-49 10400852-2 1999 OBJECTIVE: The purpose of this study was to investigate whether induction of inflammation and enhancement of cysteinyl-leukotriene (cys-LT) synthesis were involved in the augmentation of airway responses caused by IL-2. cysteinyl-leukotriene 109-130 interleukin 2 Rattus norvegicus 214-218 10400852-2 1999 OBJECTIVE: The purpose of this study was to investigate whether induction of inflammation and enhancement of cysteinyl-leukotriene (cys-LT) synthesis were involved in the augmentation of airway responses caused by IL-2. cysteinyl-leukotriene 132-138 interleukin 2 Rattus norvegicus 214-218 10384149-1 1999 Cysteinyl-leukotrienes are potent bronchoconstrictor mediators synthesized by the 5-lipoxygenase (5-LO) pathway. cysteinyl-leukotriene 0-22 arachidonate 5-lipoxygenase Homo sapiens 82-96 10384149-2 1999 Eosinophilopoietic cytokines such as IL-5 enhance cysteinyl-leukotriene synthesis in eosinophils in vitro, mimicking changes in eosinophils from asthmatic patients, but the mechanism is unknown. cysteinyl-leukotriene 50-71 interleukin 5 Homo sapiens 37-41 10391245-1 1999 The cysteinyl leukotrienes-leukotriene C4(LTC4), leukotriene D4(LTD4) and leukotriene E4(LTE4)-are important mediators of human bronchial asthma. cysteinyl-leukotriene 4-26 ubiquitination factor E4A Homo sapiens 86-93 10378985-7 1999 Cysteinyl leukotrienes bind to two receptor subtypes: CysLT1 and CysLT2. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 54-60 10378985-7 1999 Cysteinyl leukotrienes bind to two receptor subtypes: CysLT1 and CysLT2. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 2 Homo sapiens 65-71 10378985-8 1999 Most of the biological properties of cysteinyl leukotrienes relevant to asthma are mediated through CysLT1 receptor stimulation. cysteinyl-leukotriene 37-59 cysteinyl leukotriene receptor 1 Homo sapiens 100-106 10391245-2 1999 Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT1 and CysLT2. cysteinyl-leukotriene 45-67 cysteinyl leukotriene receptor 1 Homo sapiens 112-118 10391245-2 1999 Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT1 and CysLT2. cysteinyl-leukotriene 45-67 cysteinyl leukotriene receptor 2 Homo sapiens 123-129 10322101-4 1999 The second subclass, the 5-lipoxygenase (5-LO) inhibitors (zileuton) inhibits the 5-LO enzyme, which prevents the formation of both cysteinyl LTs and LTB4. cysteinyl-leukotriene 132-145 arachidonate 5-lipoxygenase Homo sapiens 25-39 10085095-9 1999 Isolation of the m-BLTR gene will form the basis of future experiments to elucidate the selective role of LTB4, as opposed to cysteinyl-leukotrienes, in murine models of inflammation. cysteinyl-leukotriene 126-148 leukotriene B4 receptor 1 Mus musculus 19-23 9442068-10 1998 These findings define a novel mechanism for regulating histamine H1 receptor activity and provide for the first time molecular insight into the mechanism by which cysteinyl leukotrienes and other external stimuli can increase histamine responsiveness. cysteinyl-leukotriene 163-185 histamine receptor H1 Homo sapiens 55-76 9774748-1 1998 In 12 operatively (stereotactic aspiration and recombinant tissue-type plasminogen activator, rTPA) and 5 conservatively treated patients with spontaneous intracerebral hemorrhage the amounts of cysteinyl-leukotriene (cys-LT) released by blood-brain cell contact were measured by the urinary excretion of their metabolites during treatment. cysteinyl-leukotriene 218-224 plasminogen activator, tissue type Homo sapiens 59-105 9620942-0 1998 Pharmacology of leukotriene receptor antagonists Preclinical pharmacological studies have demonstrated that cysLT1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. cysteinyl-leukotriene 228-249 cysteinyl leukotriene receptor 1 Homo sapiens 109-115 9620942-0 1998 Pharmacology of leukotriene receptor antagonists Preclinical pharmacological studies have demonstrated that cysLT1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. cysteinyl-leukotriene 251-256 cysteinyl leukotriene receptor 1 Homo sapiens 109-115 10222453-3 1999 The rate limiting step in the formation of cysteinyl leukotrienes is the conversion of LTA4 to LTC4 catalyzed by the enzyme LTC4 synthase. cysteinyl-leukotriene 43-65 leukotriene C4 synthase Homo sapiens 124-137 9820300-1 1998 BACKGROUND: Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent lipid mediators derived from arachidonic acid in the 5-lipoxygenase pathway that exert profound biological effects. cysteinyl-leukotriene 12-34 arachidonate 5-lipoxygenase Homo sapiens 118-132 9872059-7 1998 This review summarizes current knowledge of the structural and transport characteristics of MRP which suggest that the physiologic functions of this protein could range from a protective role in chemical toxicity and oxidative stress to mediation of inflammatory responses involving cysteinyl leukotrienes. cysteinyl-leukotriene 283-305 ATP binding cassette subfamily C member 1 Homo sapiens 92-95 9359705-1 1997 The multidrug resistance-associated protein (MRP) mediates the cellular excretion of many drugs, glutathione S-conjugates (GS-X) of lipophilic xenobiotics and endogenous cysteinyl leukotrienes. cysteinyl-leukotriene 170-192 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 4-43 9444606-6 1997 Only in the cysteinyl-leukotriene-driven pathophysiology of allergic asthma and allergic rhinitis 5-lipoxygenase inhibition appears to provide symptomatic relief. cysteinyl-leukotriene 12-33 arachidonate 5-lipoxygenase Homo sapiens 98-112 9372685-5 1997 The PAF-elicited bronchoconstriction in the transgenic mice was significantly reduced not only by a PAF receptor antagonist (WEB-2086) but also by a thromboxane synthesis inhibitor (indomethacin or ozagrel), an inhibitor of 5-lipoxygenase-activating protein (MK-886), or a cysteinyl leukotriene (LT) antagonist (pranlukast). cysteinyl-leukotriene 273-294 patchy fur Mus musculus 4-7 9359705-1 1997 The multidrug resistance-associated protein (MRP) mediates the cellular excretion of many drugs, glutathione S-conjugates (GS-X) of lipophilic xenobiotics and endogenous cysteinyl leukotrienes. cysteinyl-leukotriene 170-192 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 45-48 9313769-0 1997 Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor. cysteinyl-leukotriene 79-101 arachidonate 5-lipoxygenase Homo sapiens 117-131 9342232-1 1997 Leukotriene C4 (LTC4) synthase (LTC4S), an integral membrane protein, catalyzes the conjugation of leukotriene A4 with reduced glutathione to form LTC4, the biosynthetic parent of the additional cysteinyl leukotriene metabolites. cysteinyl-leukotriene 195-216 leukotriene C4 synthase Mus musculus 0-30 9342232-1 1997 Leukotriene C4 (LTC4) synthase (LTC4S), an integral membrane protein, catalyzes the conjugation of leukotriene A4 with reduced glutathione to form LTC4, the biosynthetic parent of the additional cysteinyl leukotriene metabolites. cysteinyl-leukotriene 195-216 leukotriene C4 synthase Mus musculus 32-37 9152370-0 1997 Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. cysteinyl-leukotriene 0-22 selectin P Homo sapiens 30-40 9152370-0 1997 Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. cysteinyl-leukotriene 0-22 cysteinyl leukotriene receptor 1 Homo sapiens 89-95 9152370-3 1997 In the present study we were interested in investigating the receptor mechanism(s) involved in cysteinyl leukotriene-induced endothelial P-selectin expression. cysteinyl-leukotriene 95-116 selectin P Homo sapiens 137-147 9152370-8 1997 The present results suggest that cysteinyl leukotrienes induce surface expression of endothelial P-selectin via a mechanism independent of the CysLT1 receptor. cysteinyl-leukotriene 33-55 selectin P Homo sapiens 97-107 8828530-2 1996 In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). cysteinyl-leukotriene 82-103 cysteinyl leukotriene receptor 1 Homo sapiens 105-119 9092565-12 1997 Microsomal GST-II, however, may also be pivotal for cysteinyl leukotriene formation in endothelial cells, and this could change our current understanding of the regulation of leukotriene biosynthesis in inflammatory disorders such as asthma. cysteinyl-leukotriene 52-73 microsomal glutathione S-transferase 2 Homo sapiens 0-17 9155156-5 1997 However, it has recently been demonstrated that MRP can specifically transport the cysteinyl leukotriene, LTC4, and some other glutathione conjugates, suggesting that MRP had a function different from P-gp. cysteinyl-leukotriene 83-104 ATP binding cassette subfamily C member 1 Homo sapiens 48-51 9155156-5 1997 However, it has recently been demonstrated that MRP can specifically transport the cysteinyl leukotriene, LTC4, and some other glutathione conjugates, suggesting that MRP had a function different from P-gp. cysteinyl-leukotriene 83-104 ATP binding cassette subfamily C member 1 Homo sapiens 167-170 8706658-1 1996 Leukotriene C4 synthase (EC 2.5.1.37) catalyzes the conjugation of reduced glutathione (GSH) with leukotriene A4 to form the intracellular parent of the proinflammatory cysteinyl leukotrienes. cysteinyl-leukotriene 169-191 leukotriene C4 synthase Mus musculus 0-23 8898379-1 1996 BACKGROUND: Cysteinyl leukotrienes (LT) are mediators involved in inflammatory and allergic disorders LTC4 synthase catalyzes the first committed step in the synthesis of these inflammatory mediators, and its cellular distribution appears to be unique. cysteinyl-leukotriene 12-34 leukotriene C4 synthase Homo sapiens 102-115 8649356-2 1996 Studies with MRP-enriched membrane vesicles have demonstrated that the protein can bind and transport cysteinyl leukotrienes, as well as some other glutathione conjugates, with high affinity. cysteinyl-leukotriene 102-124 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 13-16